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PREFACE

----------The purpose of this paper is neither to affirm nor
deny the usefulness of sulfanilamide.

Instead, this is

a report of an effort to learn something of the "mode of
action" of sulfanilamide, since so little actually is
known.
Various and varying reports of the bacteriostatic
effect of sulfanilamide have left the impression that
much, perhaps all, of the principal activity of this drug
is as yet unknown, especially since there is such a wide
discrepancy between the observed effects clinically and
the relatively feeble germ-killing powers of the drug in
the test tube.
A brief resume of the history, chemistry, pharmacology, toxicology, and therapeutics have been included
to serve as a brief review.

Toxic manifestations have

merely been mentioned for if the drug is to be used intelligently, it follows that more must be known of its
mechanisms within the body.

Therefore more experimen-

tation and test for reactions other than germ killing
power are quite in order to ascertain the drugs toxic
properties.

INTRODUCTION
Sulfanilamide, and to a lesser degree some of its
derivatives, constitute the greatest advance in chemotherapy since the discovery of salvarsan ( 92).

In the

subsequent annals of medical history it may indeed rival
this product as an alleviator of disease and human suffering.
As the reader has probably already observed, overen thusiasm inevitably follows the discovery of a new
therapeutic agent, particularly that discovery which
tends to be startling or which carries with it a dramatic appeal.

Davis (33) describes such enthusiasm by

plotting a curve, in which he lists the various phases
through which the drug passes after over-enthusiasm, in
varying degree but in definite aequence, come publicity,
commercial exploitation, incompetence and abuse, followed
by poor results, recognition of defect• and dangers, fear,
decreased use and over-correction; until, finally such
merits as may exist become recognized in their t••e light
and the new therapeutic agent reaches stability at its
proper level of usefulness (Fig. I).
Mercurochrome, mandelic acid, fever therapy and
many other therapeutic measures have had their fling
and each their appraisal.

The most recent conspicuous

example is the magic medicine sulfanilamide, certainly

.r'·

INTRODUCTION
a drug of moat unusual merit, although falling somewhat
short of enabling the internist to dispense with history
taking and physical examination and seeming now to be on
the down-grade.
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Fig. I. Trial and Appraisal: The reaction
of the medical profession toward anything new.
Considerable discussion concerning the "mode of action" of sulfanilamide has arisen during the past months
and years; but i t would be wiser first to consider natures attempts to rid the body of its infection without the aid of therapeutic measures.

Rous (III) stresses

that fact in his article "The Doctor and Nature", in which
he states that the 4octor has always deemed himself eager
to listen to nature and to carry out her commands.

He

has always spoken of aiding her, of not offending her,
-2-

IHTRODUCTION
of letting her take her course, time and again he has
conceded that "Nature is the best Physician" an admission
not the less wise because the fact has so often been
staringly evident.

The doctor has found that while he

can hurry Nature or impede her, help her, or narrow her
field of activities (as when the surgeon takes out an
organ), he can not change her ways, much less flout them.
He sees, too, that in many respects he is already wiser
than the body.

Frequently now he can go nature one bet-

ter in healing the sick through exploitation of the resources that she provides, as for example, the hormones.
In a more indirect manner, the resources of mental achievements by chemical synthesis---sulfanilamide.
said that discovery results from chance?
mind of nowdays makes its own chances.

Who was it

The prepared
It is not content

with what comes its way, but devises occasions, goes out
to find worlds of which there may be no token.
the doctor who sets forth to discover.

So it is

Domgk (35 ), by

a systematic method of experimentation found that prontosil was effective in preventing death of a dog, if administered within twenty-four hours after infection with
streptococcus.

At that time, however, he was unable to

give a definite theory as to its mode of action.
-3-

INTRODUCTIOJ:T
The doctor invents instruments and technics with
complete assurance that they will disclose things worth
while, though he may not know what.

Knowledge has come

to him in the past mostly through experimentation---which
began with the first dose ever given to a sick man; and
now he is determined to ma.ke the experimental method yield
everything that is in it.
to him:

This decision is not peculiar

as you well know, a furor for experimentation

has seized of late upon all thinking humanity.

It has

been applied even to the most delicate and lovely of human
relationships not without casualties at times, as one may
remark in passing.

However the sick man is none the worse

because the doctor as an experimenter has found that the
major laws which rule in the body of animals rule with a
striking particularity in the human organism as well:

and

from the study of diseased, lower creatures he has learned
about man (III).

This has been especially true, in the

attempt that has been made to determine the "mode of action" of sulfanilamide.

Much difficulty has been encount-

ered because of its change in reaction, when in vivo as
compared to in vitro.
Many times a drug is used before the doctor or any
one else really knows what reaction might be expected.
-4-

INTRODUCTION
Three tasks set before every doctor,---to see, to know,
and to do---are notably difficult:

he has to perceive

disease pl'Ienomena, to understand them, and to cure or
at least make them tolerable,preventing future instances.
The difficulty with this task has been that sick and well
alike have forced the doctor to act before he could know,
and to assume, for practical purposes, that he knew before it was possible for him to perceive.

Throughout

countless years people all about the doctor have cried,
nWhy don't you do something?"

At last these things have

been placed in their proper order.

A drug must first

be accepted by the Council of Pharmacy and Chemistry before it can be used by the practitioner.

In most in-

stances doseage, toxic effects, etc. have been worked
out before the council accepts the new substance.

After

such experimental data is available the doctor sees where
next to direct his energies and how to bring them to bear.
Sulfanilamide and its derivatives present a similar situation; although sulfanilamide has been officially accepted
some of its derivatives are still in the experimental stage
and their therapeutic value questioned.

-5-

HISTORY

The history of sulfanilamide as gained from a review of the literature shows that a relatively simple
compound which was known to organic chemists for 30 years
eventually found its way into the class of medicinals--first, as a component of the mo•e complicated azo dyes,
and eventually as an independent compound.
The first data on the manufacture of p-aminophenylsulphonamide is given in a paper by Gelmo ( 50 ), published in 1908.

This paper deals with a purely scientific

experiment without technical goal.

One year later

H6erlein (63) prepared together with Dressel and Kothe,
the first azo dyestuffs with sulphonamide by substituting
sulphonamide groups.

These products were used for tex-

tile purposes and were distinguished by being more fast
to washing and fulling than the corresponding sulphonamide--free products.

Allport ( 4 ) likewise gives Gelmo

credit for being the first to prepare p-aminobenzensulphonamide.

H6erlein, while working with Dressel and

Kothe on the azo textile dyes, found that one possessed
a limited therapeutic action against mouse septicemia
caused by hemolytic streptococci (
-6-
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This compound

HISTORY!

had the following formula:

0

C~Hs>NV
~1N=tf

S01HH2.

NH2.C'7_C IOI/ C/I;.

As early as 1913 Eisenberg ( 6:5} observed that cer-

tain azo dyes possessed considerable bactericidal action
in vitro and considered the possibility of the applicati on Of chyrsoidin

.H.,NQ N= No

to therapeutics.

NII,.

He, however, soon convinced himself that the product
mentioned had no therapeutic effect what ever on the infected living animal.
In 1919,Jacobs and Heidelberger ( 63) tried to increase the bactericidal properties of the quinine molecule by coupling the dihydrocuprein, to azo compounds.
In the condusion of their paper they make a note to the
effect that numerous of the new compounds show bactericidal properties in vitro (like the azo dyestuff of
Eisenberg}.

However Herlein (63 ) has found in subse-

quent experiments that the azo dyestuff made from paminophenylsulphona.mide and dihydrocuprein does not
possess sufficient efficiency against streptococci to
warrant its use. for therapeutic purposes.
llietszch.and Klarer in 1932 (II3) synthesized an
azo dye for the dye industry and obtained the patent,
-7-
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in Germany under the name of prontosil.

This compound

was a red crystalline powder, which is 0.25 per cent
soluble in cold water and has a melting point of 247
to 251 O.

During the same year, DomagM ( 36) working

with Mietszch and Klarer discovered the efficacy of these
azo dyes in streptococcic septicemia of mice, and the
chemists synthesized a new drug by adding an azo-naphthalene ring and including the sulfanilamide group.
They patented this compound which was known as streptozon, prontosil
It is the

s,

d~soduim

prontosil red, and prontoeil solution.
salt of 4 sulfonamide-benzene 2 azo

7 acetylamino 1 hydroxy-naphthalene 3:6 disulfonic acid

and is four percent soluble in cold water.

H,_Na,.sQ

N ~tfcol(ff(OC.HJ

,,._el

'SO,, Mil,.

Further investigation by Domagk (35) resulted in the
development of 2, 4-diaminoazobenzene-4-sulfonamide
hydrochloride, which was patented by Mietzsah and Klarer
in 1935 (

)

.

This compound, a brick-red powder was highly efficacious
in experimental infections of a streptococcal nature but
had the disadvantage of limited solubility and slight
-8-

HISTORY
toxicity.
Early in 1935 Domagk: ( 35) in Germany announced the
startling chemotherapeutic success with the administration of a substance to mice innoculated with hemolytic
streptococcus from a human source.

Cultures injected

into the peritoneum of untreated controls killed the
animals in 24 to 48 hours.

With doses of 1/10 to 1/50

of the tolerated dose of prontosil most of the treated
animals recovered in from 3 to 5 days, and after recovery
no pathological changes were found in the tissues, such
as were present in the controls.

To Domagk:,right-fully

belongs the credit for the discovery of prontosil as a
chemotherapeutic agent for use in bacterial infections.
Many papers on the clinical use of prontosil began making
their appearance after Domagk: made his report in 1935.
Colebrook made his· first reports in England during 1936.

J. & Mme. Trefoull, Nitti and Bovet ( 43) of

France~

in a study of azo compounds (in 1935) found that those
in which the sulfonamide group was not attached to a
benzene nucleus was inactive.

Therefore the azo linkage

was unnecessary a.nd the much simpler compound, p-aminobenzensulphonamide was equally effective.

Mouse pro-

tection experiments conducted with p-aminobenzenesulfone.mide hydrochloride verified this assumption and
-~

HISTORY
,roved conclusively that the azo linkage was unnecessary.
During the International Congress of Microbiologists
in London at the end of July, 1936, the new class of medicaments against streptococci was not the subject of a
lecture or demonstration, but it was the topic of personal
corn.rnunication and in this way Dr. Long, and Miss E. Bliss
of Johns Hopkin Hospital in Baltimore were informed at
that time by Dr. Colebrook of the success of his investigation (63 ).

Dr. Long's appreciation of the potenti-

alities of the new therapeutic agents induced him on his
return to the United States, to study carefully two products from this series, namely prontosil and prontylin.
It was Bliss and Long (74) who in 1937 concluded that,
prontosil solution, which had been subjected to reduction with cysteine hydrochloride, inhibits the growth
of beta hemolytic streptococcus in vitro.

Fuller (48 )

states that a considerable amount of sulfanilamide is
excreted when prontosil is given by mouth or by injection and he feels that the therapeutic action of prontosil is due to the sulfanilamide derived from it by reduction in the body.
Since the introduction of these drugs into this
country by Long & Bliss (1936) much experimental work
-10-
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has been done, but there is as yet much controversy as
to the manner in which the drug exerts its chemotherapeutic
effect.

-11-
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P-aminobenzenesulphonamide was first described by
Gelmo (50) in a general study of the sulphonamides of
sulphanilic acid.

He prepared it by hydrolyzing the

amide of acetylsulphanilic acid with boiling diluted
hydrochloric acid and decomposing the resulting hydro•.
chloride of

p-a.~inobenzenesulphonamide

lent quantity of sodium hydroxide.

with the equivo-

The amino-acetyl-

sulphanilic acid was prepared from N-acetylsulphanilic
acid chloride which can be produced by the action of
phosphorus pentachloride on sodium N-acetylsulphanilic.
acid dhloride which can be produced by the action of
phosphorus pentachloride on sodium N-acetylsulphanilate.
This was described as a 'White crystalline substance which
melted at 163 C.:

~s~NH,..

But Allport ( 4 ) , from a study of the compound, suggested
~he

following specifications for medicinal sulfanilamide:

Melting point:

165.0-166.5

c.

Reaction (0.5 per cent sol'u): PH 5.8-6.l
Ash:

Less than 0.02 per cent

Arsenic:

Less than lpart per million

HeaV'J metals (as lead):

Less than 5 parts per million

Sulfate and Chloride:

Trace
-12-
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Assay by total sulfur:

99.5-100.5 percent sulfanilamide.

In 1937 the Council on Pharmacy and Chemistry of the
American Medical Association (30 ) (3I ) formally adopted
the non-proprietary name "sulfanilamide" for para-aminobenzenesulfonamide.

Although the Council preferred a

shorter term, a representative of the firm, which was
the first to submit a non-proprietary product to the
Council, pointed out that "sulfanilamide" denoted the
composition and that the name was being used abroad.
Other interested firms agreed.

The Council (30) ac-

cepted the following specifications as conforming for
admission to New and lfonofficial Remedies:
1.!l:elting Point:
H.eaction:

Not less than 165 or more
than 167 C.
Neutral to litnru.s

Index of Refraction:

1.60

Halogen ion:

Negative ( 0. 5 gm. sample)

Free Ammonia:

Negative (o. 5 gm. sample)

Sulfate ion:

Negative (0. 5 gm. sample)

Ash:

Not more than 0.05 percent

Arsenic and heavy metals:

Sample shall pass test for
arsenic and heavy metals
( u. s. P. method)
Less than one per cent.

lloisture:
Carbonization in concentrated sulfuric acid. at 100 C:
-13-
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Total Sulfur (theoretical 18.6): Not less than 18.3 or
more than 18.9 per cent.
Various trade names have been given to p-aminobenzensulphonamide and as a result considerable confusion
is unavoidable..

In order to clarify this point some of

the more common preparations with their manufacturers
are given below ( 43 ) :
Prontosil Album----Bayer Products Ltd.
Sulphonamide-P-----Allen & Hanbury Ltd.
Sulphonamide-P-----Burroughs, Wellcome & Co.
Sulphonamide-P-----British Drug Houses Ltd.
Colsulanyde---------Crook'a Laboratories
P. A. B. 8.--------C.J.Rewlett & Son Ltd.
Prontylin----------Winthrop Chem. Co. Inc.
Streptocide--------Evans Sons Lescher & Webb Ltd.
Sulfamidyl---------Abotts Lab.
Sulfanilamide------Squibbs & Sons
Sulphanilamide-----Boots Pure Drug Co. Ltd.
Sulfanilamide------Council of Pharm. & Chem.
The extensive use of sulfonamide derivatives

ex~

perimentally and clinically has made it necessary to develop certain tests to determine their concentration in
the body fluid.

Marshall ( 83) devised a method for the

analysis of sulfanilamide of the blood and urine (as well
-14-
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as certain other body fluids).

It is based on diazotiz-

ation of the aminabenzenesulfonamide with nitrous acid,
and coupling the resulting diazo compound in acid solution with di-methyl and naphthylamine to produce a purplish red azo dye v1hich can easily be estimated by colorimeteric comparison.

This reaction depends upon an amino

group substituted in the benzene ring and will estimate
any compound to which the sulfanilamide is changed in the
organism and in v;hich the amino group is intact.

This

color reaction is extremely delicate, being detectable
in a solution of sulfonamide of 1:20,000,000.

Numerous

attempts to correlate therapeutic efficacy with the chemical structure of sulfonamide compounds have proved discouraging.
Most authorities now feel that it is necessary to
have the sulfonamide group in the "para" position to
provide for streptococcal efficiency ( 63).

The azo

structure does not seem to provide the azo compounds
with their therapeutic efficacy.

The necessity of having

the sulfonamide group in para-position as provision for
streptococcic efficiency as a matter of course induced
the study of other substances ( 63), outside of the azo
series, which have the sulphonamide group in para-posi-15-
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tion to other substituents.

The experiments were there-

fore logically extended to the sulphonamide compounds
of benzol, naphthalene, quinolene, and acridine series
as well as derivatives of diphenyl ether, diphenylamine,
azo methene compounds and others.

In the course of these

experiments it was found that even simple benzol derivatives with a sulfonamide group in the para-position to
an amino group were effective against streptococcus.
This simplest substance is 4-aminophenylsulphonamide:
(sulfanilamide)
The term now officially accepted by the Council of Pharmacy and Chemistry of the American Medical Association

( 63).
Although investigations in 1937 seemed to point
strongly to the para-linked sulfonamide group as the
seat of antibacterical activity, those of more recent
date appear to connect this activity with the para-linked
sulfur ( 92 ) •
The search for new and more efficacious therapeutic
agents has resulted in the development of numerous sulfonamide or closely related compounds.

Very little is

known of their properties but a brief discussion of the
most deaireS.ble will be included in the chapter on "Derivatives.

11

PHARMACOLOGY
-------~--~-~---

Pharmacology is the sum of knowledge regarding
drugs; the term is usually restricted to the study of
the action of drugs (37 ).
the

0

In this chapter however

mode of action" is not discussed; it has been set

aside as a separate chapter.

Sulfanilamide, like prontosil, acts as a relatively
indifferent substance on both the body functions and
structures, particularly after single doses ( I04).
Therapeusis with sulfanilamide has been accomplished

by the oral, subcutaneous, intramuscu&ar, intravenous,
intrathecal, 1ntrapleural and rectal routes and some
also by topical application (92 ). The oral method is
the more desirable because of its simplicity and
practicability. Unless contra-indicated by the condition
of the patient, it is by far the most desirable.

In

two series of experiments by Branham and Rosenthal {I9)

the subcutaneous route was found to be more effective.
This may, however, have been caused by the rapid absorp-

tion. (see figure 12 )

The ease with which the drug may

be taken orally seems to offset the subcutaneous method,
provided there are no gastric symptoms.
Sulfan1lam1de is readily and completely absorbed by
-I7-
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the gastro-1ntest1nal tract of the human and circulates
in the blood and other tissues almost wholly as auch(83 ) •

}

~'~
~'I

70
fO
70

'

Oral{N»lf)

--------~'o:.:.,ar.o,..I)

~

___s...,.t.(,,,.,,,)

'

Fig: .:2 Comparison of oral and subcutaneous
therap7 with sulfan1la.m1de in men1ngococcus
infection in mtce. I gram per •110 in each
case, orally (stomach tube) suspended in
acacia. s.c. 1n oil--one dose only.
Marshall and his associates found that 1n the human
subject after a s1ng1• dose of 60 grains, the maximum concentration in the blood would be reached in
from I to 4 hours, the average being about 2 hours.
Anderson ( 5) states that sulfan1lam1de soon reaches
all parts of the body, regardless of the method used
for its administration. Its distribution seems to be
governed chiefly by the water and fluid content of
the tissues. Marshall ( 81 ) found only a small amount
of the absorbed drug present in the blood stream.
Large amoun"tts were evidently taken up by the tissues.
-18-
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To investigate this point, a study was made on the dog.
The drug was found present in all tissues of the body
with the exception of bone and fat, in about the same
concentration as in the blood. That this holds also
for man has been shown by examining the spinal fluid
and blooa of an essentially normal individual as well
as one during treatment with the drug. This ready
diffus1b111ty and equal distribution is extremely
important in making sulfanilamide a successful chemotherapeutic agent.
Stewart (II8) found that after sulfan1lam1de is
administered intravenously in the normal rabbit, it
changes in form. (becomes acetylated). Immediately the
question arose, where was the sulfanilamide being
acetylated. This was soon determined by a process of
elimination. First the kidneys were eliminated by
performing a nephrectomy---the acetylation continued.

Next splenectomy and complete removeal of the gastrointestinal tract, but yet the acetylated form of
sulfanilamide could be found in the blood. Finally
the liver was removed, and the acetyl form was fowid
absent. It was therefore believed that acetylation
took place in the liver. Sulfan11am1de has been found

in the liver ( 56) and acetylation was found·,tio be

-I9-
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dependent upon aerobic respiration.
Klein ( 68) presents this schematic representation
of acetylation of sulfanilamide by the rabbit liver:
lactate---a--.pyruvate--b-..a.cetate + sulfanil1I
b
amideI

•

acetaldehyde

l•

acetlysulf anilamide
in which (a) is inhibited by anaerobiosis, thus limiting anaerobic acetylation and (b) is oxidation or
dismutation. The conjugation (c) of acetate and sulfanilamide occurs only in the intact liver cell, is
not reversible, is inhibited by high concentration of
iodo-acetamide and arsenous oxide, is only slightly
inhibited by anaerobioeis and varies greatly in
animals of the same species. It was impossible to
demonstrate the presence of an enzyme, which might
account for the coupling process found in acetylation.
Generally the process is limited by the rate of production of acetate by the tissues and may be increased
by the addition of acetate or those substances which
may yield acetate in the course of metabolism.
Sulfanilamide is almost wholly excreted by the
kidney, the normal filtering it off within twentyfour hours ( 82). The damaged kidney will hold it back
and accumulation occurs. In such instances the coneen-20-
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trat1on in the blood may rise rapidly, with resultant toxic maaifestations. It is important, therefore,
to do frequent sulfanilamide determinations of the
blood and urine. It 1a excreted very much like urea

but is reabsorbed by the tubules.to a greater extent
(SI). Marshall and his colleagues (83 ) claim that . _
V0~'-80%

of the glomerular f.iltrate is reabsorbed in

the renal tubules. Sulfanilamide is excreted by the
human and rabbit 1n the conjugated form; in the dog,
however, this is not true.

The conjugated compound

does not give the color reaction directly, owing to
a block of th.a amino group. The para.-aminobenzeneeulfonamide can be obtained from this compound by
bydrolysis with dilute hydrochloric acid(93).
Some authorities believe that sulfanilamide should
be maintained in the blood in a concentration of IO to
15 mgm. per cent. Long and Bliss (73 ) however prescribe I gram per 20 pounds for patients weighing up
'

to IOO pounds and placed the maximum at 5 gram per day
in four divided oral doses, six hours apart.
When bJpadermoclysis was indicated, treatment was
carried on

~1th

an

o.8

per cent solution of sulfan11-

am1de. The recommended schedule was IOO c.c. for
patients of 40 pounds, 200c.c. for those weighing 40
-21-
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to 80 pounds, 300c.c. for those 80--!20 pounds, and
400c.o. for all those over I20 pounds.
Do.Sages have been increased ( 77 ) ; Adul ts--3 to 5
grams for the initial dose, followed in 6 to 8 hours
by I.O to I.5 gram repeated every four hours. Children
likewise were given more and if a concentration

of

less than IO mgm. per cent appears in the blood, more
sulfanilamide is given. It has been suggested by
some authors to give larger doses over shorter intervals,
thereby causing less strain on the bone marrow. Others,
however, claim that smaller doses are just as effective
as the large doses and are therefore not indicated.
If sens1t1vit1es and idiosyncrasies of the patient
to sulfanilamide, are omitted; one is justified 1n
giving sufficient amounts of the drug to maintain a
concentration level of IO to I5 mgm.· percent. Marshall
( 80,83 ) and Proom <Io5) have devised reliable methods
for determining the concentration of sulfan11am.1de both
in the urine and blood.
Symptoms, which developed following large doses of
sulfanilamide varied considerably in different individuals

but those noted most consistently were as follows ( 57):
" Within thirty minutes after the first dose had been
taken, vertigo was experienced, and within two hours
-22-
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hyperventilation, nausea, anorexia, increased thirst
and cyanos1s were also noted. These symptoms were
accompanied by drowsiness, irritability, and very
evident mental confusion involving principally false
perception of intervals of time, extreme difficulty
in concentration and slow response to questions.
Recovery from the subjective symptoms, 1n the normal
subjects was not complete for forty-eight hours, with
vertigo, anorexia, and drowsiness persisting throughout the day following the administration."

No effects

on the blood pressure of anaesthetized cats and dogs
were noted from as much as o.I7 gram per kilo-gram
given intravenously ( 5.9 ) •
Marshall ( 62 ) gave large doses of sulfan1lamide,
about I gram per kilo., to two dogs daily by mouth for
a week but could find no consistent change in the red,
white or differential count. Likew1se,Hawk1ng (59 ),
after further investigation found no histological
changes after large doses. In the animals,which died
from the drug, Hawking found degenrative changes
(chromatolysis) in the neurones of the anterior column
of the spinal cord and some in the nerve cells of the
cortex and mid-brain.

Rabbits receiving 0.25 gram

prontosil per kilogram of body weight for twenty-one
-23-
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consecutive days presented red, white and platelet
counts, which ran closely parallel in the treated
and untreated animals ( 70 } • Necropsy findings
suggested early bone marrow depression.
The symptoms suggest that in acute poisoning by

large doses of sulfanilamide the stress falls ma1n1y
on the central nervous system, apart from dyspnea
which is presumable due to the formation of sulfhemoglobin ( .59. In cats there seems to be a transient
paralysis of the cerebral cortex for a few hours;
in rabbits the cortex is only depressed.
In concluding, it may be pointed out that the
symptoms described have little significance in human
jherapy, since they were obtained only by the use of
very large doses. It has not been possible to trace
any case of nervous symptoms in a human being attributable

to sulfanilamide or allied compounds.

A review of the literature discloses a remarkable

number of reports in which mildly unfavorable collateral reactions and:. occaslo!}ally death have accompanied
the therapeutic use of sulfanilamide compounds. These
various manifestations,

name~

(I}fever (2) acidosis

(3) cyanosis (4} nausea & vomiting (5} vertigo and
·(6) various blood ch~n~ea will be discussed in the

chapter on

11

Toxicity 11 •
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The intelligent use of any drug demands that its
mode of action shall if possible be understood, since
special circumstances may a.rise in which such knowledge
alone can dictate the right course to adopt.
It is perhaps scarcely necessary to point out that
the use of these drugs

imperatively demands a bacter-

iological as well as a clinical diagaosis. The drug is
not specific for septicemia,

meningitis, or pneumonia

but :for infections by certain bacteria wherever: situated,
while on other species it has little or no effect ( 49).
It interferes in some way with the activities of these
bacteria in the body, but the question is, how?
Our knowledge of the ultimate mechanism of sulfanilamide 1 s action in vivo is at best rather meager ( 92 ) •
In attempting to explain the therapeutic effect of the

red prontos11s and sulfanilamide two theories have been
dominant ( 62); the one, that this effect was chiefly
due to a direct action of sulf anilamide upon the
coccus; the other, that any such action is only,ancillary to the operation of the cellular defense mechanism
of the body.
In the discussion of these two theories, I have
attemptea. to group the lead.ins authorities under the
-2>..
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proper heading.
Direct Action of Sulf anila.mide upon the Bacteria
Levad1t1 and Vaisman quoted by Domagk (36) in their
research came to the conclusion that the encapsulation
of the streptococcus which took place,norJllally, before
phagocytism, was hindered or prevented by prontosil.
Domagk (36) disagreed for he believed that encapsulation should be a preventative stage and not one that
invites phagocytism. He thought the first phase of the
chemptherapeutic effect of prontosil was its conjugation with the infective agent and later stimulated
phagocytosis.
J<1ellon and Cooper (83)

suggested the possibility

of virulent organi,... being transformed into their
non-virulent phases, as a r.esult of prontosil treatment. In order to substantiate this theory, Mellon (91)
employed immune hoBse-sera prepared from two anomalous dissociants of a hemolytic streptococcus from a
human case of cellulitis. Patients responding to this
treatment often show the streptococci in a definite
transition from tnttr mucoid or matt to intermediate,
smooth or rough colony forms.
Hoerlein (6J) thought that the

possibil:t~y

of

combating infectious diseases with chemotherapeutic-26;;..

MODE OF ACTION
ally active substances depended to a large extent
upon the structure of the pathogenic organism. The
more highly developed the organism, the more points
for attack it offers to the action of the chemotherapeutic substances. Dr. M.Fischer, quoted by
Green (52), believes the mode

o~

action of sulfani-

am1de is that of a general protoplasmic poison.
Colebrook (

2a

demonstrated capsule formation

by the virulent "Richard's" strain of streptococcus
in the blood with, as well as without prontosil. The
possibility that cocci in the treated animals might
cease to elaborate certain toxic products which may
be directly responsible for death was considered but
nothing in its sup•t was found.
Blood or serum of human beings and monkeys taken
after the administration of sulfanilamide or prontosil
was found by Colebrook et al. (27) to have a bacteriostatic

or

bactericidal action against hemolytic

streptococci greatly in excess of anything encountered
in normal blood or serum. Fuller (48 ) claims that
prontosil as such has little or no streptococcalkilling power, but that the bactericidal action is
derived from the sulfanilamide, a reduction product
of pront,9sil. Bliss anctLong ( IG also found para-
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aminobenzenesulphonam.ide to be the active

bacterio~

static substance.
Experimental work by Long and Bliss (I6,I7,I5,'4,73

77 ), revealed a greater bacteriostatic action on
one of the hemolytic streptococci than on the other
two. The difference beirween the Ellis on one hand and
C203 and Schw on the other was observed repeatedly.
The mode of action was of utmost concern, for streptoco ccic multiplication was inhibited by the chemical
but in addition it was felt that the streptococci must
have been damaged to permit such a marked degree of
phagocytism( 74) •

Capsular formation however, as

suggested earlier by Levaditi and Vaisman was not
found. Although explanation of the exact mechanism of
action on the streptococci is impossible, it is important to note, that the change brought about by sulfanilamide therapy was not instantaneous, see fig. 3.

llrs.

(,

,. ,,_

t'

7

Fig. 3. Growth curve
stra n Ellis in normal
ho~se serum broth, & in normal horse serum broth conta:2,fn1ng sul.fanllamide.

MODE OF ACTION
A period of several hours was required before the
change began to develop. This suggested the possibility of a union between the organism and chemical by which a marked change in the metabolism
of the streptococcus was brought about ( 77). Inhibition of growth and phagocytosis of the organisms occurred 6 to 8 hours after the administration
of the chemotherapeutic agent, indicating that there
may have been some change in the organism or chemical
substance,73). Buttle et al. (24) rurwever, demonstrated
a slight bactericidal effect for sulfanilamide in
whole blood invitro, but in deleucocyted blood there
seemed to be no difference in diminution of rate of
growth; a point against, direct action on the bacteria.
It is also extremely difficult to rule out the bactericidal effect of serum from patients with hemolytic
streptococcus infection' 3!).
Finkelstein-Sayliss et al. (4!) found that sulfanilamide was highly soluble in fats and they felt that
it was very likely concentrated in the fatty envelope
of the streptococcus. Experimental work seemed to
bear out their contentions. The results show that the
streptococci pollulate very rapidly in the presence of
sulfanilamide; when the peak of growth is reached the
-29-
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population falls away extremely fast, see fig. 4 ..
With increasing age of the cultures this rise and fall
becomes progressively less pronounced and in the 26
hour strain, the organisms are almost immediately
susceptible to the bactericidal action of sulfanilam1de. the young forms took up more fat than the

.
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Fig. 4. fable & Graph showing the effect of
sulfanilamide over a period of 24 hours; first
stimulation and then depressionof growth.
older culture. Two explanations were offered: {I) that
with the diminution of the

percen~age

of fat as age

increases, the concentration of sulfanilamide in the
fat of each individual cell or organism increases,
and this increase is responsible for the bacteriostatlc
action upon the older cultures; or (2) that sulfan11-30-
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amide acts first as a stimulant and secondarily as
a depressant.
In spite of the vast amount of work that has been
done to ellicit the mechanism whereby sulfan1lam1de
produces the desired clinical results, it still
remains a mystery.

Barron and Jacobs { 9) found

that prontylin had a slight inhibiting effect on the
oxidation of glucose by the hemolytic streptococcus,
however the conditions under which this was done are
not given.

Bigler et al. (I4) claims the action 1s

independent of the leucocytes; Gross, Cooper, and
Peebles (53) also disagree with Long and Bliss, for
they found no stimulation of phagocytotis as described.
According to Gross et al. " the degree of protection
observed in splenectomized mice was identical with that
obtained in the normal animals. 11

Therefore one may

conclude that the reticulo-endothelial system plays
a very minor, 11r any, role in producing clinical results.
Thus far very little if any effect on the heAolyt1c
activity of the staphylococcus and streptococcus hemotoxin has been observed (54).

Green (

5~

presented a

theory of the activity of Comgo Red ( a sulfanilamide
derivative), in which he feels that the activity is due
to its electro-nei:r8.t1ve properties and that invading
-3I-
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bacteria

c~ng

positive charges are electrically

rendered harmless. This is as yet purely theoretical
and has no definite proof.
Perhaps one of the most recent attempts to secure
information. as to the mechanism of action of sulfanilamide upon the streptococcus was made by Warren,
Street, and Stokinger (

I2~,

who measured the effect

of this drug upon the oxidation-reduction potentials
of the hemolytic streptococcus. It was found that
sulfanilamide caused an elevation of the 0-R potential.
The means whereby this deviation was produced remains
at present obscure.
Although

many more experiments no:t;Jhentioned,

might be included to argue for ndirect action on the
bacteria •1

,

we shall

turn our attention to the

second theory.

ODlt
Ancillary to the Operation
e ense MechanISm of the Body:

Sulfanilamide,
£!_ the Cellular

As was mentioned earlier in the chapter Domagk (36 )
believed that prontosil was conjugated with the infective agent but later stimulated phagocytosis.

Mellon

and Bambas ( 9Q however, were convinced that. other factors
aided in the destruction of bacteria. Experimentally
they were able to show that tlb.e;almost negligible effect

-32-
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of sulfanilamide on minute streptococcus 1nnocula,

3 to 6 organisms, might under appropriate conditions
be amplified to an extent reminiscent of the human
voiee's intensification by a loud speaker.

Incred-

ible as it may seem, this effect was brought about
by employing "physiological" or normal salien instead
of broth in the ordinary routine of diluting the
streptococci to the minute innocala, so necessary for
the quantitative bacteriostatic test. A I5 to 30
minute exposure to salien had an inhibitory effect (90)
but it was so slight, as ordinarily to be considered
negligible.
Yet this apparently negligible effect lasting only
a few hours became a critical one when "potentiated"
by dilutions of at least I:I00,000 sulfanilamide, in
the presence of normal serum • .Mathematically, the
situation 1s one where I plus 2 plus 3, instead of
666~

adding up to 6, comes to.66 or conceivabl'
is what is meant by the use of the term:

11

This

potent1ationn

a phenomenon well known to pharmacologists.

Acting

alone none of these factors would be capable of
accomplishing the aesirect bacteriostatic result; but
acting to-gether, their effect is multiplied, so that
a critical end result is produced ---- in this instance

-33-
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complete inhibition of bacterial growth {90).
Subtended is a representative table 11lustrating

the situation (see fig.
Diluent

...

Broth

Medium
Broth

"
t1

ti

,....

5).

Cone. o:r
Sulfanilamide
0

I:4,ooo
I:I0,000

Serum
(undiluted)
O
"H
"
I:4,000
NaCl
I:I0,000
"
ti 0 .85% Broth
0
It
H
1:4,000
II
I:I0,000
"
fl
Serum
fl
(undiluted) O
"
I:4,ooo
"II
11
I:I0,000

No. of
Hours
Coccr-seeded 6------24
0
4
IOOO
0
500
5
0
500
5

5
6
3
I8
0
0

8
0
0

IOOO
500
IOOO
400
50
200

0
0
0
IOOO
400
500

50

IOOO

0

0
0'

0

Fig.5. This table presents some of the experimental
evidence supporting Mellon and Bambas' theory of
"potentiation".
Buttle et al. (24) confirmed Mellon and Bambas theory,
that the primary mechanism was one of mutual reciprocation between sulfanilamide and the bacteriostatic powers
of the host. This was demonstrated in de-leucocyted
blood or culture medium, in which a definite diminution
in the rate of growth did not appear.
Osgood

Cro)

maintains that eulfan1lam1de itself did

not kill the organisms but rendered them vulnerable to
bactericidal substances present in the normal serum,
probably by preventing the formation, or by neutral-

-34-
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ization, of toxins or aggreseins of the organisms. He
claimed that culture of human marrow makes possibae
a type of control not attainable in animal experimentation or in clinical investigation. Much experimental evidence (Iob supports

the view that bacter-

icidal substances must be present in the serum of the
animal, be developed, or be introduced from another
source if sulfan1lamide is to save lives.

As yet it

is not known, whether this action on the toxins or
aggressins may be due to the destruction o! some
substances necessary for their formation, to a direct
action on the organism preventing the formation of
toxins or aggressins, to the destruction of nascent
toxins or aggressins, to their destruction after
formation, to catolysis of a.n anti-toxin ---- toxin
reaction, or to a sufficiently slow rate of production
so that they are destroyed by the natural processes
of oxidation as rapidly as they are formed. It has
been found that sulfanilamide does not affect the
dehydrogenasee of the pneumococcus (S9), therefore
any inhibitory action which the drug produces must
be by augmenting the body defenses.
Branham and Rosenthal. (19 ) demonstrated better
therapeutic resul.,ts when using com-binat1ons
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and drug. A synergistic action seemed to exist, since
the increased effectiveness of combined therapy was
greater than the additive effects of the drug.and
serum alone.
Finkelatein and Birkeland (40 ) in an attempt to
analyze the significance of the various factors which
aight play a part found; (I) that when leucocytes were
well washed with plasma (2) that when leucocytes were
treated with varying dilutions of the drug and then
well washed (3) that when streptococci were treated
with varying concentrations of the drug and then washed,
no more phagocytosis occurred than in the controls.
It appears that serum or a factor in it is necessary
to obtain the effect of the drug. The phagocytoais of
hemolytic streptococcus was enhanced in vitro but fresh
serum or plasma appeared to be necessary for completion
of the reaction. Not only did these drugs increase the
number of bacteria phagocytosed per leucocyte but also
the number of leucocytes taking part in the reaction

(99 ).

Just how sulfanilamide enhances phagocytosis

is not clear, but our results (40 ) briefly reported
here (see fig. 6) suggest that sulfanilam1de or a
serum-sulfanilamide complex acts as an opsonin.
If sulfanila.m±de is a strept-oeoecic anti-toxin,
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it would not be unreasonable to expect it to behave
much like anti-toxins. This was shown· by Kemp ( 65)
in attempting to neutralize streptococcus toxin with
dilutions as high as I:I,000. Neutralization did not
occur, neither could any anti-hemolytic quality be
exhibited.
Dil. or Drug
I:I,000
I:I0,000
I:S0,000

l"-

No. of Cocci
.. ~1ocytosed
192
246

% of leucooytes
laking part
20 %
32

%

60 %
I: I00,000
296
48 ·~
!:250,000
82
12 %
Control
96
I6 %
Fig. ~~ The effects of var7B:g dilutions of
sulfanilamide on the phagocytosis of hemolytic
streptococcus.
5!4

· Locke et al. ( 72) emphasized the "fitness rating"
as an index of condition and capacity for resistance.
Rabbits with high fitness ratings accomplish the
removal of intravenously injected pneumococci from
the blood more rapidly than rabbits with lower ratings.
Treatment with sulfanilam1de and especially and especially with sulfanilamide plus fitness-promoting adjuvant tends to keep the blood stream clear

eno~h

of

pneumococci invading from the infected focci, to permit
the natural defensive forces to get an upper hand.
Adolph and Lockwood ( 2 ) believe sulfanilamide pro-
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vides a tissue environment in which the cocci are
unable to multiply freely and to invade adjacent
tissues as well as the blood stream.

Kolmer (69)

likewise agrees that sulfanilamide apparently restrains
the growth of beta hemolytic streptococcl and thereby
facilitate their phagocytosis.
Negative results

have been obtained by McKinley

et al. (86) in treating experimental virus infections.
One of the essential differences between virus and
bacterial infections is that the former are invariably
of an intra-cellular nature while the latter are chiefly
inter-cellular, though in some bacterial diseases cellular invasion is also characteristic. It is suggested
that sulfanilamide is unable to exert its action ( ?--~-bacteriostatic,

infecting

virustatic or what-not )

against the

agent when it has invaded the tissue cells

as in the case of virus infections. The efficacy of
sulfanilamide in specific bacterial diseases may depend
partly on its successful attack against

ext~cellular

organisms, while the host cells themselves are contributing to the defense against the invading microbes.
On the other hand, we may assume from present evidence
that viruses find conditions within the tissue-cells
favorable, rather than unfavo.Pable, for survival and
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multiplications.
Summarizing the various theories, which have been
mentioned in this chapter we find that the "mode of
actionu is still a mystery.

Bell (II) concludes that

inhibition of bacterial division occt.rs in vitro and
in vivo. This effect is enhanced by serum and tissue
cells. Degenerative changes 1n the organisms are inconstant and do not influence virulence or toxin production on even the first sub-culture. The toxins remain
but seem incapable, in the presence of sulfan1larnide,
of destroying cells except in infections more massive
than those encountered clinically. The type of cellular

response remains dependent on the host; is not

in itself drug-conditioned. Phagocytosis is enhanced
indirectly through bacteriostaSis b•t is not related
to drug action on body cells, although opson&n production appears to be hastened under drug-altered conditions. Host supremacy is ultimately dependent on biologic response to the invader. The drug seems to
inhibit the multiplication and spread of bacteria and
protects cells from the destructive influences of
infective organisms, thereby inducing a more favorable
environment for opsonin production and the action of
other host

p~tective

mechanisms.
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----------------------------Realizing the impossibility of summarizing the
.el:tl.liaal results of sulfanilamide. since its discovery;

I have attempted to review the literature of 1938 and
use, the summary of Bel.ion, Gross, and Cooper ( 93) for
a review of the clinical results prior to 1938.
" ?he diverse clinical manifestations- caused by the
hemolytic streptococcus, regardless of the organs affected, or the severity of the attack, have yielded to the
S"!_lfonamide compounds in a uniformly sat1sf actory
fashion. Not only has the mortality been convincingly
reduced in its more malign manifestations, but in those
more difficult to assess with this sole critetf.on, the
course and complications of the diseases have been
profoundly modified.
Meningitis, with a mortality approaching IOO per
cent, puerperal sepsis, with its 25 per cent mortality
and cellulitis with sepsis----to say nothing of
peritonitis-----all have responded to these compounds
in an impressive manner. The reduction of meningitis
mortality in a fair sized series of cases to approximately 15 per cent is in itself arresting; but when
this is often associated with a prompt sterilization
of the spinal fluid under oral a&nini strati on of the
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drug, the results are nothing short of dramatic. And
while scarlet fever has not been critically studied
as yet, it appears that its course and complications
have been favorably affected.

or

note too have eeen the results 1n erysipelas ·

where a total of I,000 cases had a mortality rate of
less than one per cent. Moreover, the all important
age factor has been invoked as a criterion in the study
of a sizable number of these cases. Observed aide by
side with a series having the most approved alternate
form of treatment (antitoxin and ultraviolet radiation)
the verdict definitely favor•d the sulfonamide compounds.
Conditions of lesser severity such as tonsillitis,
cystitis, pyelitis, mastoiditis, and lymphangitis,
have evoked uniformly favorable responses. And in certain mixed infections where the streptococcus plays
an important role, such as Ludwig's angina and gas
gangrene, the advance reports, while not sufficient
1n number to reach a conclusion, have been sufficiently

favorable to justify further tr1a1.•
These authors continue their summary (93) ----"About 80 percent of I4I cases of gonorrhea treated
with sulfanilamide

hav~

been reported cured. These
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patients, however, have not been followed sufficiently
long to allow conclusions regarding the permanence of
the cures.
Although only 12 cases of men1ngococcal meningitis
have been treated with sulfonamide compounds, the
percemtage of cures (91.7) 1s impressive; and for the
same reason the single report of II cases of Type III.
pneumococcal pneumonia is arresting.
Infections of the urinary tract caused by E.coli
and in some cases by staphylococci have been reported as
cured in about 75 per cent of over ISO cases. The findings of renal irritation or of clear-cut nephritis
have been reported in more than IS cases in which this
condition was secondary to erysipelas or other hemolytic streptococcal infections. For the most part
all signs of the complications disappeared under
sulfonamide therapy.
The few favorable reports of gas gangrene, certain
skin diseases, and of quartan malaria await confirmatory
evidence of larger numbers of cases.
Difficult of evaluation or distinctly unfavorable
are the reports dealing with typhoid and undulant
fever, non-hemolytic streptococcal infections,

ious arthr1t1s, Hodgkin's disease,
-42-
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other conditions of unknown etiology."
An at.tempt was made to summarize the clinical

results of sulfanilamide therapy during I938,by
tabulating all the cases reported.

I

found however,

that such an attempt was futile; for,many of the journals
were foreign, some were not being subscribed for by
our 11bBary, and others were either being bound or in
use. Therefore the results, as listed in this table, a.Be
at best very meager. It has been included to give the
Disease
No.of Cases
- -17
Canine Ditemper (in dogs)
Chancroid
IO
Genito-urinary Diseases
348
Gonorrhea
207
Ludwig's Ansina (strept.)
I
Meningitis (gonorrheal)
2
"
( 1nfluenzal)
3
"
(meningooiccic)
IO
4
"
(otic)
"
(pneumoooccic)
2
"
(staphylococcus)
I
11
(streptococcus)
!2
I
Orbital Cellulitis
Paratyphoid ttB'' Carrier
I
Peritonitis (pneumococeic)
I
Poliomyelitis (in monkeys)--no good.
Pneumonia
6
Various Infections
I24
Vulvo-vaginitis (in children)
67

Cures

lb

IO

303

I5I

I
2
I

IO

4

2
I

8

I

I

I

6

Il$
34

reader an idea, as to the effectiveness of the drug
and the many diseases for which it is being used.
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-------------Toxic symptoms usually develop following large
doses of a drug or 1n those individuals, who are
extremely sensitive to it.
exception.

Sulfan1lamide is no

Vertigo, hyperventilation, nausea,anorexia,

dermatitis, cyanosis, aggranulocytosis, anemia and
aulph. & methemoglob1nemia were the most consistent
symptoms (57). ihese symptoms are usually accompanied
by drowsiness, irritability, and very evident mental
confusion involving principally false perception,
difficulty in 9oncentration and slow response to
questioning.

Recovery from the subjective symptoms

in the normal subjects is not complete for forty-eight
hours. Most symptoms usually disappear rather promptly
after the administration of the drug is discontinued.
In the discussion of the individual toxic symptoms,
the more frequent ones shall be considered first.

CYAN OS IS
Cyanosis, frequently observed in patients receiving
sufan11amide therapy, seems to be almost generally
attributed to sulfhemoglobinem1a or methemoglobinemia.
Few writers, however, have actually identified these
derivatives in cyanotic patients. Ches1ey (25) reported
eight cases showing cyanosis after sulfanilamide therapy,
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1n which sulfhemoglob1nem1a and methemoglob1nem1a were

ruled out.

.Mull and Smith 65) were also unable to

demonstrate methemoglob1nem1a and sulfhemoglobinemia
by spectroscopic examination.
Marshall and Walzl ( 84 ) admit that sulfhemoglobin
as well as methemoglobin may occur under certain oondi tlons after administration of sulfan1lamide, but it
seems clear that these abnormal iron pigments supply
by no means the only and probably not the main, explanation of the cyanosis so frequently encountered in
using this drug.
Payne ([Olf) believes that methemoglob1nem1a is an
important factor 1n producing cyanos1s, but he has
found the gray discoloration of mucous membranes and
skin persists in both humans and dogs long after
methhemoglobin and sulfhemoglobin have disappeared
from the blood. It is possible that this residual
discoloration may be explained by the presence of
small amounts of paraphenol 1n the blood and tissues
especially since accwnulations of a foreign brown
pigment may be observed by microscopic examination:
of the tissues. A similar mechanism may be applicable

to

sulfan1lamide.
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Marshall et al. quoted by Ottenberg (102) , have
demonstrated that the respiratory function of the
hemoglobin is unaltered. Methemoglobin and

sulfhemo~:.

globin have been found in some cases but in amounts
far too small to explain the intense cyanosis. Ottenberg (I02) states that whole blood whether arterial
or venous, has a chocolate brownish tinge.

Al though

aerated gains oxygen 1n normal amounts, it does not
become bright red but remains dark.

This led Otten-

berg to seek for a derivative of sulfanilamide in the
erythrocytes. He and his co-workers were able to
reproduce the phenomenon in vitro by use of ultra-violet
light. This they believed might offer an explanation
for cranosis in vitro but remains questionable in vivo.
King and Leslie ( 67 )

found no instances of

anoxemia, nor any 1n which the oxygen saturation was
low enough to explain the relatively marked cyanosis.
These observations tend to indicate that diminished
oxygen saturation of the arterial blood does not play
a significant role 1n cyanosis. This is 1n keeping with
the clinical observation that the administration of
oxygen fails to relieve cyanosis.

Mull and Smith ( 95 )

however found an actual lowering of the capacity of the
blood for oxygen and they belie•ed oxygen was indicated
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as well as something to increase the capacity of the
blood for taking up oxygen.
CEREBRAL MANIFES'rATIONS

Long et al. ( 7~ list dizziness, nausea and headache

among the common cerebral t.oxic effects. These manifestations hav.e seldom been severe enough in ward patients
to warrant discontinuing administration of the drug. In
ambulatory patients these symptoms may constitute a
serious problem. Alcohol is contra-indicated during
sulfanilamide therapy as it tends to accentuate the
cerebral toxic manifestations. Patients who are receiving
sulfanilamide should be warned against driving automobiles,
because tho dizziness and decreased mental acuity sometimes seen may render them dangerous on the road.

FEVER

Simple fever unaccompanied by other toxic manifest-

ations occurs frequently.

Occasionally the question

of :C_d:ifferentlating the drug fever from fever caused by
some infection, causes difficulty.

Long and Bliss (

7~

regard a simple fever, a fairly common toxic manifestation
in the course of sulfanila.mide therapy. The question
of whether one may resume treatment with the drug after
the fever has disappeared is of importance. A test dose

( 5 grains)

to patients who have previously had a febrile

response is certainly indicated. If a sharp febrile
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response is noted within twelve hours 1t is unwise to
continue the drug.
Hageman and Blake ( 55) during a study of a series

of cases treated with sulfan1lam1de, t'c:nmd, th.at'.·a
characteristic febrile reaction was encountered in a
fair proportion of the cases.

The similarity between

drug fever and serum sickness was rather striking. The
time interval, the fever and the rash are characteristics
common to the two. Since the reaction occurs after the
drug has been decreased in dosage or even discontinued
suggests that it is not the immediate concentration of
-"I"'

sulfanilamide 1n the oo¢y at the time of the reaction
which 1s responsible for the drug fever but rather

~·,

that sulfanilamide itself or in a combined or changed
form is antigenic. 'l'hus far attempts to :throw light
on the mechanism of the reaction have failed.
ACIDOSIS
Acidosis 1s the condition in which acids are
absorbed or formed in excess of their elimination or
neutralization, or in which there is an excessive
loss of bases from the body ( 26) •
Southworth ( II1) 1n a series of fifty cases was
ab1e to show two with clinical acidosis. Therefore a
series of fifteen consecutive prontyin-treated patients
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were studied.

Every single case

~howed

some fall 1n

the C02 combining power of the blood plasma. It 1s
generally conceded that the

co 2

combining power may

be Slightly·lowered as long as the temperature is
elevated but no specific studies of streptococcal
infections are recorded. In one case, the patient, when
afebrile and suffering from no streptococcal infection,
the C02 combining power fell from 59.8 volumes per cent
to 37.2 volumes per cent after the ingestion of 6.9 gm.

ot prontylin.
Many physicians advise taking sodium bicarbonate
with sulfan1lam1de to prevent acidosis; sodium lactate
however has been found to be more desirable for it
produees less gastric disturbance•
Hartman et al. {57) consider the question of
acidosis entirely on a physiological basis. When the
reduction of the base bicarbonate in the serum has

o

reached the level at which, despite the decrease in
carbonic acid brought about by the lll.yper-ventilation,
the ratio of the bicarbonate ; carbonic acid has again
reached the normal value of 20 : I, then there is no
further need to excrete bicarbonate into the urine,
and the latter may again become normally acid. At this
time, the pH of. the blood should be lower than it was
.49...
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when bicarbonate was being excreted 1n excessive amounts,
and the data confirms this expectation. The

co 2

content

of the serum at this same time would still be reduced
because both the bicarbonate and carbonic acid levels
are below normal. It is easily conceivable that with
this existing bicarbonate deficit, a true acidosis
might develop, should ketosis, lactic, or other acid
accumulations occur; or, on the other hand, should the
pyperventilation suddenly cease, allowing carbonic acid
to accumulate.

DERMATITIS
Sulfanilam1de therapy may result in several distinct
types of dermatoses, but before entering into a discussion of the distinct types, a description of the
dermatitis will be given.

The eruption is distributed

over the face, occipital portion of the scalp, neck,
shoulders and arms downward to the mid-portion of the
backs of the fingers ( 5I ) .

The lesions are more

numerous on the extensor aspects of the arms than on
the flexor surfaces. On the face the outlines of the
individual lesions are only faintly discernible because
their borders had fused into one another to form

a;._

diffuse and patchy erythematous process. The eruption
stopped at the aairl1ne in front and on the sides but
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was continuous below with the lesion on the neck. Its
outstanding characteristic was its limitation to the
regions of the skin, which had been exposed to
sunlight ( 46 ) •
of~

di~ect

The affected zones were clearly set

from the normal skin by the line of clothing at

the "vtt of the neck, by sleeves rolled up to the elbows
or in the region of the ankles.

The hands are fre-

quently swollen out of proportion to the degree of
symptoms that existed elsewhere.
Newman and Sharlit {98)'found that if patients receiving sulf anilamide were exposed to direct sunlight
for five hours, an eruption of the skin developed within twelve hours after the exposure. The eruptions
were similar and characteristic. They consisted of
numerous scattered, irregularly grouped macular plaques,
varying in size from that of a pea to that of the palm
of the hand. As the lesions progressed, they became more
confluent. The color was a deep red with a violaceous
tinge, the exact hue is aptly described as maroon.
Moderate itching accompanied the dermatitis but scaling
was not present.

Frank ( 46 ) offered the suggestion

that heliosensitivity created by the drug or some of its
chemical reactions with hemoglobin might play a part
in this type of toxic reaction. Thie would help account
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for the infrequency of this type of toxic manifestation
in the numerous cases reported, because the patients
have been predominately hospitalized.
Schwentker and Gelman

(II~

found the entire body

surface usually affected, but in some cases was limited
to the buttocks or the legs. The mucous membranes are
apparently unaffected and the lesions seldom

p~oduce

severe 1tcb.1ng. The rash develops very rapidly without
prodromal symptoms in most cases.
Summarizing~

the reported clinical findings (42,II2,79

94, & 96 ), we find that sultanilamide therapy may result
1n several distinct types. of toxic dermatoses ( I2I).

The first and most common type is precipitated by expo-

sure to sunlight. In this type the level of suifanilam1de 1n the blood is not abnormally high, nor is there
ordinarily a sensitivity to the drug. However, the
combination of factors occurring internally, such as
disease processes: .and the irritative effects of the
sun's rays, results in the occurrence of a localized
dermatitis which may be complicated by areas of dermatitis at distant points.
The second

t7pe of dermatitis is that ln''.Wh1ch'

definite sensitivity to the drug occurs,·resultlng m-a *eneit1.zat1on

dermatitis~
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tolerate further .sulfanilamide 1n any dose.
The third type of dermatitis is that resulting from
poor toleration of, or saturation with, sulfan11am1de
and presenting the typical picture of toxic dermatosis.
It is, therefore,important that the clinician be
able to differentiate these three types of dermatitis,
and there-by be able to institute the proper therapeutic
measures.

AflGl:WWLOCYTOSIS

Past experiences with drugs synthesized on a benzene

base prompted predictions of toxic manifestations involving the hematopietic tissues, and this theoretical
prognosis has been borne out 1n practice ( I3). Kracke,
quoted by Young (I28), presented evidence that aggranulocytosis might be caused by amido-pyrene, phenacetin,
certain gold salts and arsphenamine. These drugs pessess
1n common the benzene ring with an attached NH2 , or

amine group, which increases the ease of oxidation. A
consideration of the formula of sulfa.nilamide suggested
the possibl1ty that this drug might also be capable of
producing aggranulocytosis.
Allen and Short ( 3 ) .have tabulated the eight cases
of aggranulocytosis caused by sulfanilamide ( see fig.8).
Sulfhemoglob1nem1a, acute hemolytic anemia, and
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leucopenia have shown improvement on discontinuation
of the drug. Granulocytopenia, however might make its
appearance even after cessation of therapy(I28) •
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Domagk, quoted by Bresgen ( 20), claims that repeated
small doses over a long period of time will eventually
lead to an exhaustion of the marrow cavities and result
1n leukopenia and aggranulocytosis. Larger doses over

t

shorter intervals are -considered most desirable. Jennings
and Southwell-Sander (64 ) found it impossible to state
the exact amount of sulfanilamide needed to produce
aggranulocyto•~s.

In thttr case the size of the dose

appeared to be the important factor. As soon as immature
erythrocytes or a leucopen1a appears, therapy should
cease immediately.
Schwartz, Garvin, and Koletsky (II4) found pathologic
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changes consistent with aggranulocytosis. The myeloid
series of the marrow showed maturation arrest with
stem cell hyperplasia and absence of more mature cells.
There was reduction in the nucleated red blood cells
and many degenerate forms----consistent with secondary
anemia.

~hey

believe from these observations that

sulfanilamide exerts a toxic effect on both the red and
white blood cells.
Bigler et al. { I4 ) attempted to determine the
leukocyte response to sulfan1lam1de therapy by making
daily counts before, during and after administration of
the drug. In no instance was an increase in the leucocyte
count found. They did believe, however, that the drug
caused a depression of leucocytes, not only because of
instances of leucopenia but because of the spectacularly
rapid fall in leucocytes at the end of an infection,
which is often followed by a moderate rise in leucocytes
after the drug is discontinued. The alteration in the
leucocyte response was in the nature of a marked absolute
reduction of all the cell elements without an;. characteristic relative change. The granulocytes were not reduced
out of proportion to the other cells, and at no time
were toxic changes demonstrated. The Schilling differential in most cases reflected, what one would consider
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a healing infection.
McGuire ( 85) demonstrated a rapid decline in the
total white count of a pat!ent given sulfanilamide,
after having recovered from a leukopen1a developed
two months before.· Whitby (

I2~

found that after cess-

ation of the drug, the hemoglobin and leucocyte count
returned to normal (see fig.

---------•"'

o

Do.ys

r

J'•). He believes that

Fig.9. Graph shows the
course of recovery of hemoglobin and leucocyte count
1n a patient who had been
given a continuous daily
course or 3gm. for four
months.
,o

,,

.20

dangerous aggranulocytosis is undoubtedly due to
idiosyncarsy, in the same way as with amidopyrine;
particular care being necessary with debilitated patients.
Blood examinations however do not always forecast a
sudden disaster, therefore one must

wa~ch

for clinical

signs as well.
ANEMIA

fhe anemic condition usually develops rather rapidly.

There may be sudden"'masa1ve hemolys1s as indicated by
an accompanying icterus, a rapid drop in hemoglobin,

r
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and the appearance of urobilinogen in the urine (107).
At the same time the patient appears very toxic and ill,
although there may be little or no fever. The blood
count shows marked anemia, with evidence of

regenera~ion,

both in the red and white cell series. Large numbers
of immature cells may present a clinical picture of
leukemia.
The mechanism of the producti'on of these anemias is
as yet unknown, but it does not seem to be of the nature
of a true idiosyncrasy (72 ). It is probable that the
anemias represent an abnormal susceptibility on the part
of the red blood cells of certain individuals to severe
hemolysis by sulfanilamide.
Harvey and Janeway ( 58) reported three cases of
severe anemia but were unable to prove that sulfanilamide
was responsible for the rapid hemolysis. They ruled out
hemolytic jaundice, sickle-cell anemia and paroxysmal
hemoglobinuria, but their attempt to reproduce the
clinical picture met with failure. Careful blood studies
revealed no significant changes.

In a case, reported

by Wood (127), the hemolytic streptococcus was considered
a factor 1n producing hemolys1s; however the clinical
. indications were that the infections had subsided during
therapy.
-57-
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The resemblance of these hemolytic anemias to the
hemolytic crises produced by the use of phenylhydrazine is quite striking (58 ). It is possible that
these individuals produce from the sulfanilamide a
small amount of the toxic product having an action like
phen7lbydrazine or produce such a substance much more
rapidly than the average patient. !herefore with the
possibility of an acute hemolytic anemia in mind, blood
counts should be taken at regular intervals, to note
the initial changes of the blood picture. The drug thereby being with drawn previous to the symptoms.

SULFBEMOGLOBINEMIA AND METHE»OGLOBINEMIA
Sulfhemoglobinemia is formed in vivo and becomes
dangerous if the total hemoglobin falls below thirty
perceeilt. As mentioned under the heading o:t"CYANOSIS!'
sulfhemoglobinemia frequently accompanies cyanosis,
although it is not considered the essential factor in
producing cyanosis.

( 6

According to Archer and Discombe

), hydrogen sulphide is constantly being absorbed

from the large gut; being formed therein by the action
of bacteria on food residues, or as a result of the
administration of elementary sulfur, which is known to
be absorbed partly as a sulfide.

This absorbed hydrogen

sulfide is, under normal conditions partly destroyed by
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the plasma and partly excreted by the lungs. If a
grossly excessive a.mount of
normal amount of

H~S

2

HZ3

is formed, or if a

is formed, when a catalyst for

the combination of hemoglobin with H2S is present 1n
the blood, some of the sulfide will combine with the
hemoglobin in the erythrocyte; and since this cell,
which has a:. 11fe of several weeks, is not lysed, will
1n the course of time develop a detectable sulfhemoglobinemia. The time which will elapse before sulfhemoglobin is detected will depend upon the a.mount of

H28

absorbed from the gut, on the nature and quality of the
catalyst administered, and the detection of

sulfhemo~

globin.
There are two possible causes of sulfhemoglobinemia;
namely, idiosyncrasy and overdose. A normal dose is an
overdose to a sensitive patient( 47).
Pa.ton and Eaton (
tration of Jig 804

IO~

have found that the adminis-

simultaneously with, or within two

or three days preceding sulf an1lam1de gives rise in
most persons, to sulfhemoglobinemia. In the absence of
sulphates, large doses are well tolerated. Archer and
Discombe ( 6 ) provide the following explanation of
KgS0 4

increasing sulfhemoglob1nemia------"Magnes1um

sulphate breaks down into magnesium and sulphate ions;
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the magnesium ions form an insoluble material and
increase

the osmotic pressure of the gut contents

so that the body fluids pass to the gut lumen. The
more liquid contents of the colon form an admirable
medium for bacterial growth; further, by the action
of purges the absorption of food is decreased, and
more passes to the colon unabsorbed. Since many
bacteria normally present in the colon split cystine
to hydrogen sulphide, an increased production of
hydrogen sulphide may be expected. Therefore any
treatment which helps the formation of liquid stool
may be expected to accelerate the formation of
sulfhemoglobin.
Bensley arid Ross ( I2 ) found

methemoglo~inemia

to be present with relatively small doses as well as
large doses of sulfan1lam1de. They found that it
usually disappears after the drug is discontinued.
Stoness CII9) likewise reports a case, in which the
patient became cyanotic after the second day of
sulfanilam1de administration. After the drug was
stopped the methemoglobin disappeared.
Cyanosis due to methemoglobin disappeared ver1
rapidly (after cessation of the dl:'ug), while sulfhemoglobinem1a was much more persistent (Io3 ) • Oxygen
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relieves methemoglobinemia, whereas nothing helps
sulfhemoglobinemia; methemoglobinemia passed off
in twenty-four hours and sulfhemoglobin is
eliminated by the liver 1n six weeks.
'l'OXIC NECROSIS OF THE LIVER

Massell and jones-(

) reported one case of

toxic necrosis of the liver following the use of
sulfanilamide. The patient, a white male, 37 yrs.
of age was treated for a gonorrheal infection.
After receiving 500 grains, he developed a headache
and felt weak. His urine became dark, amber colored;
and he developed a fever and rash. The drug was
discontinued with the appearance of toxic manifestations.
Six weeks later, the patient noticed a tear at the
urethral meatus, and on his own volition without
seeking advice, took fifteen grains of sulfanilamide.
Within five hours he developed a rash; three days later
he became jaundicea, the urine appeared dark and the
stools were gray. At that time there was no anemia or
hepatomegaly. The patient left the hospital, against
oraers; only to be readmitted one week later with the
clinical and laboratory picture of acute toxic necrosis
of the liver. The patient was deeply jaundiced, anorexic
and vomited profusely. The liver margin extended three
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tmgers.:.be,low the costal margin. After one week he
developed some urinary suppresion coinciding with a

c·

high N.P.N. retention. Intravenous glucose was given
1n repeated doses and the patient responded favorably.

TOXIC OPTIC NEURITIS
This condition does not seem to occur often but will
be

included here to serve as a reminder of the pessible

toxic effects, manifested by sulfanilamide.
Bucy ( 23) reported a case of optic neuritis, which ·
apparently developed as a result of the aruuinistration
of sulfanilamide. The drug was given on three occasions
----the first two; headache, cyanosis, diarrhea and a
choking sensation developed. On the third, there was a
severe loss of vi•ion due to toxic optic neuritis
following 0.3 gram of sulfan1lam1de.
A brief tabulation of ti1e complications of sulfanil-

amide in a series or two-hundred nases has been appended
bJ

Fitzgibb6n'r and: Silver (

), see fig.IO on next page.

In conclusion let it be borne in mind that this
chemotherapeutic agent has many toxic effects, and beeaase
of them the patient should be carefully supervised while
sulfanilamide is being administered. This supervision
should consist of careful clinical abservations, frequent
and regular temperature recordings, a daily hemoglobin
-62-
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determination and a daily total white blood cell
count. If these procedures are adhered to as a routine,
the toxic manifestations of sulfanilamide will be
noted in their inception.

I

Symptom
Ho. of Points
Weakness
72
Dizziness
67
Dyspnea
60
Headache
33
Anorexia
32
Drunk feeling
25
22
Sleepiness
General aching
I9
Cyanosis
I9

•

Percentafe
of poin s
36
33
30

I6.5
I6
12.5
II
9.5
9.5

Vomiting
9
Fever
8
Ra.sh
II
Constipation
6
2
Diarrhea
Paresthesia
4
Cycloplegia (temp.) O
Peri. neuritis
0
Pre-cordial Pain 2

4.5
4
6.5
3
I

Temporary 4eafness 2
I
Urticaria
Toxic necrosis of Liver
Death
0

0.5

Comment
most frequent

02

tent for
one patient

50%

photo-sens.

2

0.5
0

I

0.5
0.5

I

One case known
outside this series
One case reported

0

Fig.IO. Incidence of s14e-react1ons in 200 consecutive
cases of gonorrhea being treated with sulfan1lamide.
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The development of sulfa.nilamide therapy, which
at present occupies the attention of the medical
profession all ever the world, is now being extended
to new compounds derived from the original prontosil
and sulfanilamide.
The original prontosil was a water-insoluble basic
azo-dye (sulfamido-chrysoidin) suitable for oral
administration only, and for the purposes of parenteral
therapy the sodium salt of an acid dye ( disodium 4sulfamidophenyl-2-azo-7-acetylamino-I-bydroynaphthalene

3, 6-disulfonate) had to be evolved.

It was found by

a series of clinical investigations that, when used
early, it was a remarkable remedy for the cure of
erysipelas and to be helpful in treating puerperal
fever and certain other hemolytic infections.
As a result of studies by Fourneau and his coworkers
at the Pasteur Institue in Paris, it was soon found that
this complex dyestuff owed much of its virtue to the
fact that it was evidently reduced in the body to the
simpler compound, p-aminobenzenesulfonamide, and that
this relatively easily prepared compound was equally
eff eoti ve in experimental inf actions { I ) •

'rhis

discovery provided investigators with a simple and
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easily accessible material which has been studied
extensively from all aspects, and much work baa been
devoted to modifying and improving this parent substance with the object of increasing its efficiency,
widening the range of bacterial diseases which can
be influenced, and reducing its toxic but rarely fatal
effects. Although thousands of such compounds have
been synthesized, hundreds have been tried exper1mentall7 1n animals, and a dozen or more have been used
clinically, few have come into practical use.
Whitby ( I2!j bas classif'ied those compounds which
have exerted interest, or which have been found worthy
of clinical trial, into the following groups:
I. Those in which substitution has been made
in the amino group: sulfamido-cbr7so1d1n; prontosil
soluble; benz¥1am1nobenzenesulfonam1de (Proseptazine) ; and loluseptazine.
2. Those in which one hydrogen atom of the
sulfonam1do group bas been substitued: Uleron;
2-(p-am1nobenzenesulfonam1do) pyridine (Dagenan);
4, 4 1 -diam1no benzenesulfonanllide; 4-amino-4' dimetbylaminobenzenesulfonanilide; and 4,3'..;d1a.m1nobenzenesulfonan111de.

3. Compounds of the sulfone type which are chemically unrelated to the sulonam1dea: 4,4'-acetamidodiphenylsulfone; and 4,4'-d1aminod1phenylsulfone.
In the first group, including sulfonamide itself,
there is activity against hemolytic streptococci of
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groups A, Band

c,

but not D and F, meningococei and

gonococci, but none against the pneumococci with the
exception of type III, which is itself virtually a
streptococcus. Toxicity and solubility are altered,
rather than efficiency or range. Multiplication of
sulfonamide groups tends to extinguish activity. In
the second group the range of activity 1n most has
been increased to include at least pneumococcus, and
they possess an equal if not greater activity against
bacteria affected by the first group. Out-standingly,
the best member of this group is 2-(p-amino-benzenesulfonamido) pyridine, (2-sulfanilyl-am1nopyr1dine).
With regard to the sulfones, the range of activity is
again extended to include pneumococcus, and efficiency
against hemolytic streptococcus is increased; but
toxicity has rendered many of them unsuitable for clinical trial although the di-(p-acetylaminophenyl)
sulfone has been successfully introduced as a welltolerated remedy against streptococeic, gonococcic,
and pneumococc1c diseases, and the sulf'one "Prom1n 11
has been shown to be of great value 1n the treatment
of exper1menta1 infections in animals.
In order to shorten this paper, only two of the
more popular derivatives w111 be included in this
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discussion, namely: Neoprontosil and Sulfapyridine.
Neorrontosll
eoprontosil is disodium 4-sulf amido-phenyl-2azo-7 -acetylamino-I-hydroxynaphthalene 3,6-disulfonate.
It occurs in the form
of a dark red, tasteless,
odorless powaer, soluble
in water, but virtually
insoluble in organic solvents.
Neopronosil is well adapted for peroral use by reason
of its somewhat

su~erior

efficiency (I09, 8) and rela-

tively greater therapeutic margin of safety by this method
of administration as comps.red with parenteral administration. According to Barlow (8 ), the minimum lethal
dose of Neoprontosil, when administered by mouth cannot
be accurately determined in mice due to high tolerance

and limited gastric capacity o# the animals. However it
exceeds 40gm. per kilo of body weight as compared with
the minimUIIJ lethal dose of 6.25 gm. per kilo of sulfanilamide administered orally.
Raiziss et al. (I04, in a comparative study of four
sulfonamide compounds, determined that neoprontos11
exerts almost the same therapeutic effect by mouth as
doea.sulfanila.mide.. Of 30 mice 1n1'ected with a virulent
I""'·.
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culture of beta-hemolytic streptococci, treated daily
with IO mg. of sulfanilamide by mouth. 77 per cent
were protected for seven days, and 66 2/3 per cent for
twenty-eight days. Of a corresponding group of mice
similarly infected, but treated with IO mg. of Neoprontosil daily by mouth, 77 per cent were protected
for seven days and 63 per cent for twenty-eight days.
Barlow ( 8 ) pointed out that the minimum protective
dose varies directly with the virulence of the culture.
The theory that the activity of N,eoprontos11 is
due solely to the sulfanilamide liberated through reduction in the body is not universally accepted.

An increasing number of investigators incline to
the view that the different components of the complex
Neoprontosil molecule contribute to its specific effect.
Brown and Bannick ( 22) have felt for some time that
the relation of Neoprontos11 to sulfanilamide

is pecul-

iar and not clearly defined. If, as has been sug@ested,
Neoprontosil is tffective only in direct proportion to
the sulfanilamide released, it is difficult and puzzling to understand the excellent results obtained with
from 40 to IOOc.c. of Neoprontosil 2.5 per cent solution
(containing in IOOc.c. only II grains or 0.73 Gm. of
sulfanilam1de). As these

~.uthors
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seems inevitable that unless one wished to attribute
such satisfactory results to the small amount of
sulfanilamide, it must be assumed that Neoprontosil
is capable of producing other added chemotherapeutic
actions in the body.
Gross, Cooper and Lewis ( 54 )

and their coworkers

presented data to show that Neoprontosil----but not
sulfanilamide-- showed significant

ne•traliz~ng

power.

This property consists in the ability of the drug to
inhibit hemolysis of hemolytic streptococci.
King, Henschel and Green ( 66 ) also reported that
colonies 1n culture mediums containing I:IOOO Neoprontosil are surrounded by smaller zones of lysis, 1n relation to their size, than in control sets, indicating
that the amount of hemolysin available for erythrocyte
destruction is moderately reduced.
'lolerance
Carefully conducted clinical investigations have
demonstrated that side effects are less frequently
observed and are generally less severe after Neoprontosil
than after sulfanilamide. Herrel and Brown ( 6I ) recently stated that the "accumulated experimental and
clinical evidence also tends to indicate that the tox1c1ty of' Neoprontosil is comparatively low. This low
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toxicity of Neoprontos11 1S particularly impressive
when comparison is made with the toxicity of sultanilamide." Many of the patients who were intolerant
to sulf an1lam1de were successfully treated by these
authors at the Kayo Clinic with Neoprontosil (oral).
A number of the pat.ients showed leukopenia; as the
physicians were unwilling to administer sulfan1lam1de
tor fear of further depressing the leukocyte count,
N.eoprontosil ( oral) was substituted, with the result
that the white count returned to normal. Furthermore,
the compound was administered orally in two cases of
cholangitis and in one case of jaundice without any
evidence of increased hepatic injury.
Bannick, Bro·wn and Foster ( 7 ) observed only
I5.4 per cent of reactions in 96 cases. They remarked
that untoward symptoms, when they occurred, were
generally mild. Slight fatigue and vertigo were noted
in several eases. Mild symptoms of gastro-intestinal
irritability appeared within the rirst day of treatment,
though these were subsequently avoided by giving the
drug an hour before meal time. In four cases, nausea,
vomiting and cramps led to discontinuance of the drug.
Cyanosia, insufficient to hinder treatment, was detected
1n four cases. Only one patient became acutely ill from
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the drug. This patient suffered chills, fever and vomiting. However, recovery was immediate oft.discontinuance
of treatment. A number of patients who were unable to
tolerate sulfanilamide were successfully treated with
Neoprontosil ( oral ) without experiencing untoward effectll
It must be remembered however, that patients having a
sensitivity or idiosyncrasy to the preparation may experience side effects similar to those which have been reported with sulfanilamide (see chapter on "TOXICOLOGY").
Clinical Considerations
In a report. by Bennick, Brown and B'-oster ( 7 ) of
the Mayo Clinic concerning the use of Neoprontosil (oral)
in 96 cases, including I2 cases of ulcerative colitis,
the patients ranged 1n age from I3 to 83 years. The
average total dose in the course of treatment was 26.5

Gm., while the largest dose received by any patient was
90 Gm.

!he duration of the traatment was, on the average,

about seven days, the longest course extending over a
period of twenty-five days. These authors recommend the
administration of Neoprontosil one hour before meals,
since gastro-intestinal
symptoms, though usually mild,
.
were relieved by giving the drug when the stomach was
relatively empty. Slight fatigue and vertigo, occasionally noted, did not constitute a severe annoyance. As
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has been stated, no evidence of renal irritation was
revealed by urine analysis. The patients were informed,
however, that the urine and occasionally the stools
would be discolored red. In most instances where counts
and morpllological examination of the blood cells and
hemoglobin estimations revealed changes, these could be
considered as associated with the primary disease.
There was pronounced improvement in each of the nine
cases which were uncomplicated.by

othe~

disease.

In a later paper Brown, Herrell and Bargen { 21 )
presented further observations on the clinical use of
Neoprontosil alone in chronic ulcerative colitis. Eight
cases were treated in all. In each case there was marked
improvement within a few months. The results obtained
in a few cases reported in this series led them to conclude that early cases with mild to moderate involvement
of the bowel offered the best opportunity for this type
of therapy.

Naturally, when the disease has existed for

some time with resultant anatomic deformity of the bowel
and changes in the physiologic function with its attending manifestations, a chemotherapeutic agent directed
against the infective process may hardly be expected to
be entirely effective.

Using Neoprontosil in those infections which have
-72-

DERIVATIVES OF SULFANILAhiIDE

been shown to be responsive to sulfan1lam1de, Herrell
and Brown (61) treated approximately 150 patients
suffering from infections due to the hemolytic streptococcus, pneumonia caused by the pneumococcus in which
specific serum was not available, chronic ulcerative
colitis, cholangitis, osteomyel1tis, cutaneous manifestations, such as lupus erythematosus, pemphigus, etc.,
as well as other infections caused by organisms which
have not responded satisfactorily to sulfanilamide.
Although the result of the therapy in each individual
case was not reported, these authors felt that in
general " they seemed to justify the opinion that the
therapeutic influence of Neoprontos11 (oral) approximates to a condiderable extent that exerted by sulfanilamide." In infections caused by organisms which have
failed to respond to sulfanilamide, successful results
were naturally not obtained with Neoprontosil ( oral ).
Dr. Josephine B.Neal ( 97 ) of the New York City
Department of Health refers to the peroral administration
of Neoprontosil • She found that that in treating such
bacterial diseases, particularly meningitis, which re"'
spond to sulfanilamide compounds, the use of Neoprontosil orally was followed by rapid and remarkable improvement. In<the event the patient could not swallow or retain
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medication by mouth, Neoprontosil was administered
parenterally. Occasionally, it was given intraspinally with similar results.

SULFAPYRIDINE
The research for chemical substances active against
bacteria led to surveys of compounds effective against
the pneumococcus but although, from time to time,
substances more active than sulfanila.mide were discovered, most had the

dis~dvantage

of being relatively toxic.

Yfhi tby (125), on May 1938, was able to report that
the compound 2-(p-aminobenzenesulfonamido)pyridine,
now widely known as sulfapyridine, is chemotherapeutically active in experimental infections 1n mice against
pnewnococc1 of types I,II,III,V,VII,VIII, and especially
against types I, vu: and VIII, and that moeover, the
compound had promise of being efficient in the treatment
of experimental hemolytic streptococcus and meningococous
infections in mice. Successful therapy has also been
reported in regard to meningococcal ( 34), gonococcal(IO,,
72

) , staphylococcal ( 29), and streptococcal (45 )

infections.
Biochemical and B1o1ogical Data
Sul:fapyr1d'Iiie ( "i&B.693";-"Dagenan") was one of 46
new compounds prepared by A.J.Ewins and M.A.Ph111pps
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1n the chemical research laboratories of May & Baker,
Ltd., at Dagenham, Essex, England, in a search for a
substaanee witll a sufficient degreeof activity against
the pneumococcus to justify its use in the treatment
of acute lobar pneumonia { I).
"Dagenan" is a white, or nearly white, powder
melting at I90.5-I9I.5 degrees

c.

and having a slightly

bitter taste. It is soluble in water to the extent of
0.28 Gm. in IOOOc.c. at Z7 degrees

c.

and is sparingly

soluble in the the usual organic solvents. It has both
acid and basic properties and is therefore soluble in
acids, forming stable solutions below a pH of 4. Due to
the activity of the SOZfH 2 hydrogen it is also soluble
1n alkalies, forming solutions with a pH of IO to II,
(see structural formula given below).

11,/to

-/-HN-

The drug, ;,which has· been called' by Yarlous na.mes ... -sulfan1lam1de~pyridine,

sulfone-pyrid1ne, pyridine

sulfanilamide compound, dagenan, M&B 693, finally was
named sulfapyr1dine by the Council on Pharmacy and
Chemistry ( 32) •
Evans and Gaisford (38 ) recommend the following
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dosage;

..

I-3 months ---- 0.8 ~- daily
6-24 ..
I.5 ti"
3 yr.
2.0
"

___ .......

5

------

ff

3.0

"

Mac Coll ( 78) reports the use

ti

or

sulfapyridine in

33 children. The most successful results were obtained
1n 13 pneumococeal infections. All the patients showed

marked improvement with1n 48 hrs., regardless of the
day of the disease on which treatment was begun. Temperatures usually reached normal in 20 to 48 hours with an
average of 36 hours. The true crisis of lobar pneumonia
was not seen but, rather, a rapid lysis. In general ,
the course of the pneumocoocic patient was one of marked
improvement during the first da.JI with relief of malaise,
and some fall in temperature. During the second day the
appejiite improved. Resolution usually began with the
fall in temperature.
Toxic effects such as vomiting, cyanosis, methemoglobin formation, and a fall in hemoglobin during
treatment have been noted and indicate that the same
caution must be employed as with the use of sulfanilam1de.
Long et al.

(74 ), on the basis

or

the

experimen~al

and clinical evidence available prior to February 1939
concluded that

car~ful

therapeutic trials of the effects
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of sulfapyridine in pneumococcic, severe staphylococcie
and Friedla.nder's bacillar infections seemed waranted.
but that good evidence was not at hand that the drug is
as effective as, or superior to, sulfanilamide in the
treatment of hemolytic streptococcus, meningococcus,
gonococcus or Welch bacillus infections.
Mode of Action
---- ~he main theories advanced for the action of the
sulfonamide drugs 1n bacterial

in~ections

postulate

stimulating action on the body defenses; neutralization
of toxic bacterial products; action on the bacteria as
germicides, or by interference with invasive power and
ability to multiply rapidly; and the combinations of
these actions.
Fleming { 44 ) believes there is simple inhibition
of growth (and possibly of toxin production) and while
the organisms growth is stopped and its vitality lowered, some a.gent 1n·:.t.ae body damages the capsule or
perhaps causes autolysis. The &load serum is thought to
contain the active principle. He believed that the bacteria were rendered more susceptible to phagocytosis
by the polymorphonuclear leukocytes and the monocytes.
This conception agreed perfect1y with that of Long and
his coworkers ( 74 ) but was somewhat in opposition to
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the conclusions of Whitby (I25 ) •
It is probable that the efficacy of sulfapyridine
depends on its ability to inhibit the growth of the
pneumococcus---irrespective of type---and it has been
suggested that the drug interferes with the mechanism
whereby the cocci utilize serum proteins as foodstuffs.
Recovery presumably depends, however, on the patients
ability to develop specific antibodies to neutralize
the pneumococcus carbohydrate substance_ and cause a
degradation of the infecting organisms ( I

)•

Bacterial Chemotherapy
"This rational explanation that the sulfonamide
drugs are not simple germicides, but probably act by
neutralization of some metabolic function or enzymic
activity, awaits a complete solution through the
labors of a bacterial chemist. It has already been
noted that, though both sulfanilamide and sulfapyridine
are equally effective in blocking the vital food for
streptococcus, the latter is decidedly more effective
in blocking :Cbat for pneumococcus. Rosenthal ( 108 )
once suggested that ultimately we may be able to
devise a specific cb.emotb.erapeutic agent for each. t9pe
of bacterial infection and, eventually, for the various
-7'8-
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virus diseases. With the present theory of specific
interference with food assimilation, or with some
factor essential for multiplication, the hope for an
antibacterial chemotherapy based on sulfur compounds
may be fulfilled since that--in the sulfanilamides,
their derivatives, homologs and analogs--organic chemistry can provide the biochemical and clinical

worker

with compounds 1n infinite variety. The possible defense
available to bacteria against a specific drug of the
sulf an1lamide type would be the development of resistant strains for, as Hans Zinsser has remarked, 'though
actually complex in function and metabolism, these
supposedly simple things ( the bacteria, protozoa, and
viruses) display an amazing biological and chemical
flexibility, and the phenomena of infection constitute
an accelerated evolution extraordinarily favorable for
the observation of adaptive changes.' To combat this
evolutionary defnse shift a suitable change in the
chemical constitution of the drug might be all-necessary
and essential. Whatever the future may bring, so much
has been accomplished 1n the four short years since the
introduction of the sulfanilamides that the future is
bright with hope in the battle against the bacterial
and virus diseases that plague mankind.H

-79-

(

I

)

•

BIBLIOGRAPHY
--~--~~----~-~--

I. Ad41nall, C.R. *'Sult'apyr1d1ne"
The Merck Report

48:II-I4'39

2. Adolph, P.E. & Lockwood, -J .s.

"Studies on the
Mechaniam of the Actio.n of Sultan11am1de•
Arch. Otolaryng. 27:535-551 '38

3. Allen, J.G. & Short, C.L. "Granulocytopenia associated
with sulfanilamide theraPJ"
Hew England. J.Med. 219:6-8 '38

"Research paper: P-aminobenzenesul~
phonamide"
Q,uart.J.Pbarm. & Pharmacol. 9:560-6 '36

4. Allport, N.L.

.

5. Anderson, E.G.E. "Chemistry & Mode of .t.ction of

Sulfan1lam1de and related compounds"
Rhode Island M.J. 2I:I3I~l34 '38

6. Archer, H.E. & Discombe, G. • Sulthemoglobinem1a;
cause and prevention with reference
to treatment"
Lancet 2: 432-435 '37
7. Bannick, E.O.; Brown,A.E.; & Foster, F.P. "therapeutic effectiveness & Toxicity of
8ulfan11am1de & several related
compounds"

A.K.A. III:770-777 '38

8. Barlow,

o.w.

- "Relative Toxicities of Therapeutic
Agents; of the sulphonamide type•

Proc. Soc. Exper. Biol. & Med. 37:315318 '37

9. Barron, E.S.G. & Jacobs, H.R. "Effect of Prontos11

and Pronty11n on the metabelism of
bacteria 11
Proc. Soc. Exper. Biol. & Med. 37;IoI I 1 37

.L: C. ;

IO. Batcb.ellor, R

Bees , R. ; Murrell, ll. & Bra1De , G.
"M&B 693 1n treatmeat of ~onorrhea"
Br1t.M.T. 2:II42-II45 38

BIBLIOGRAPHY
II. Bell, R.A.

"Sultan1lam1de and Chemotherapy"
U.S.Haval Med. BU.11. 37:73-II2 1 39

I2. Bensley, J.B. & Ross, J.B. "Methemoglobinemia
due to therapy"
Canad.M.A.J. 37:62-64 '37
13. Berg,

s. & Holtzman,

H. "Fatal granulocyto:r.enia
following sulfan1lam1de Therapy'
A.M.A. II0:370-37I '38

I4. Bigler, J.A.; Clifton, W.M. & Werner, M. "Leucocyte
response to suli'an1lam1de therapy"
Ai'ill.A. II0:343-349 '38

IS. Bliss, E.A. & Long, P.H. "Act1vAt1on of Prontosil
solution 1n vitro by reduction with
cystine hydrocblor1Ae"
Bull. Johna. Hopkins Hosp. 60: 149153 1 37

,&
, "The Mode of Action of
------- Sulta.nilamide"
•••••• 109:1524-1528 '37
17. _____ ,&
,
.. The failure of' p-aminobenzenesulphonamide therapy in urinary
tract infections"
·
Hew England J •.Med. 2I7:I8-2I '37

I6.

IS. Borst, J.G.

"Death from aggranulocytosis after
treatment with prontosil flavum"
Lancet I:I5I9-I520 1 37

19. Branham, S.E. & Rosenthal, S.M. •studies in
Chemotherapy n
Pub. Health Rep. 52:§85-695 '37
20. Bresgen,

c.

"Etiology of Aggranulooytosis"
Klin. Wcbnschr. 17:273-2'75 '38

2I • Brown, A.E. ; Berrell, W.E. & Bargen, J.A.
"Heoprontosil in the treatment of
chronic ulcerative ool1t1s"
Proc. Staff lfeet. Mayo Olin. I3:56I565 '38

'f..

BIBLIOGRAPHY

22. _ _ _ _ , & Bann1ck, E. C. "uae of Sulfan1lam·ide

and Prontosil solution"
Proc. Staff Keet. May Cl1n. !2:644-

648

23. Buoy,

P.c.

t

37

"Toxic Optic Neuritis resulting from
sultan11am1de"

A•.M.A. I09:I007-I008'37

24. Buttle, G.A.H.; Parish, H.J.; Mcleod, M. &
Stephenson, D. "The chemotherapy of typhoid and
some other non-streptococe1e infections
1n mice"
Lancet 1:681-684 '37

25. Chesley, L.C.

"cyanosis without sulfhem9globin.or
methemoglobin 1n patients receiving
sulfanilamidett
J.Ol1n.Invest1gat1on 17:445-447 '38

26. Christian, H.A. "The Principles and Practise of
Medicine" J>.Appleten-Century Company,

New York, N.Y.

1938

27. C.olebrook, L.;. Buttle, G.A.H.; O'.Meara, R.A.Q,.
The mode of action of p-aminobenzenesulphonamine and prontos1l in hemolytic
streptococcal infections"
Lancet 2:1323-1326 '36
28.

,

Ken.DJ, 1'. " Treatment of puerperal
infections, and experimental infections
1n mice with prontosil"
Lancet 1:1279-12$1 '36

&

29. Council on Pharm. 6 Chem. "Sultan1lamide (the council
name for p-am1nobenzenesu1phonam1de)"

A.M.A. I08:I340 '37

30.

, "Sulfan1lam1de and related

------~----~lo~,-m-po-·unds"

A~M.A.

I08: 1888

1

3I. ~~~-------~----' "Sulfan1lam1de"
A.M.A. 109:358 1 37
"Sulfapyridine 11
~----~----------'A.M.A. 112:~9
~ ' 39

2:7

BIBLIOGRAPHY
"Prostatectomy or Hesection?"
A.M.A. II2:68I '39

33. Davis, E.

34. Dimson, S.B."Bulf'apyridine in :Meningitis"
Lancet 2:424-426'38

"A Symposium on the Chemotherapy
of Bacterial Infections"
Deutsche med. Wchnschr. 61:250-3 '35

!5. Domagk, G.
36.

-----

,

"Chemotherapy of Streptococcal
Inf'ections"
Xlin. Wchnschr. 15:1585-1590 '36

37. Dorland, W.A.N.
"Definition"
Medical Dictionary, W.B.Saunders Co.
Ph1ledelph1a, 1934
38. Evans, G.M. & Gaisford, W.F. "Treatment of pneumonia
with Sulfa.pyridine"
Lancet 2:I4-I9 ' 38
~9.

Fenton, W.J. & Hadgkiss, F. "Staphylococcal septicemia treated by M & B 693 11
Lancet 2:667-668 '38

40. Finkelstein, R. & Birkeland, J.M. "Mode of Action
of sulfan1lamide and prontosil"
Science 87:44!-442 '38

4I. _____-Satliss

H.; Paine, C .G. &: Patrick, L.B.
The bacteriostatic action of p-am1nobenzenesulphona.m1de upon hemolytic
streptococci"
Lancet 2:792-795 '37

42. Finney,

4!. Fitch,

J.o.
w.K.

44. Fleming, A.

"Severe dermatitis medicamentosa
following administration of sulfa.nilamidett
A.M.A. I09:I982 1983 '37
"ihe nomenclature and dosage of the
new anti-streptococcal preparation"
Practioner 139:680688 •37

"Anti-bacterial power of blood of patients
recre.ivi.ng sulfapyr idine"
Lancet;564-~67 '38

BIBLIOGRAPHY
45.

action 1n vitro of
------sulfapyr1'1ne on pneumococc1
and
,

0.Aiit1-bacter~al

streptococci"
Lancet 2:74-78 '38

46.

lr.ank,

J •.L. ~Dermatitis from sulff1ilamide ( after

exposure to sunlight)
A.M.A.I09:IOII-IOI2 '37

47. Frost, L.D.B. "Sulfhemoglobinemia following ant1streptococoal chemotherapy"
Lancet 5IO-$I4 1 37

48. Fuller, A.f. "Ia sulfanilamide the active agent 1n
prontosil therapy?"
Lancet I:I94-I98 '37
49. Garrod, L.P. "The chemotherapy of Bacterial Infections"
Lancet I:II75 & II78 '38
50. Gelmo (Jour.f .Prakt.Chemie 77:372) quoted by
Hoerlein, H.
M.Rec.I46:II-I3'37
51. Goodman, M.H. & Levy, c.s. ~Development of cuta11eous
eruption (toxicodermatosiS) during
administration of sulfan1lam1de"
A.M.A. Io9:I009-IOII 1 37
52. Green, 11'.L.

"Sulfanilamide and ite related cpmpounds"
J. Indiana M.A. 31: 294-295 •38

53. Gross P.; Cooper, F.B.; Peebles, M.L. "Effect of
splenectomy on the therapeutic action
of sulf anilamide on mice infected wi)h
hemolytic streptococci"
Proc. Soc. Exper. Biol.·& Med. 36:311313 '37
; "Inhibition of
54. ____ ; _ _....,....._;
Streptococcic hemolysin by sulfan11amide compounds"
Proc.Soc.Exper. Biol. & Med. 38:275279 '38
55. Hageman, P.O. & Blake, F.G. "Specific febrile reaction"
A.M.A. Iot:642..:.646 '37

BIBLIOGRAPHY

56. Harris, J.8. & Klein,J.R.

Acetyla.tion of Sulfan11am1de, by the liver tissue 1n vitro"
Proc. Soe. Exper. Biol. & Med. 38:
78-80 '38
0

57. Hartman, A.F.; Perley, A.M. & Barnett, :1 .L.
"Pbfs1ologic effects of sulfanilamide;
Changes in acid base balaace"
J.Clin. Investigation 17:465-472 '38

58. Sarvey, AJaM. & Janeway, C.A. "Development of a.cute
hemolytic anemia 11
A.M.A. I09:I2·I6 '37

59. Hawking, F.

"Pharmacological Actions of Sulf anilamide"
Lancet 2:IOI9-I020 37
1

60. Helmholtz, H.F. "use of sulfanilamide in treatment
of urinary tract Infections"
Proc. Staff Meet. May Clin. 12:444-446
'37

61. Herrell, W.E.; & Brown, A.E. "Gl1n1cal use of
Neoprontos11 11
Proo.Staff Meet. i~.ayo Clin. 13:555560 '38
62. Hoare, E.D."Baetert.al changes induced in human
blood and serum by sulfanilamide"
Lancet I:655-659 '38
63. Hoerle1n,

new class of chemotherapeutic
agents against streptococe1 11
M.Rec. I46:II-I3 '37

H. "A

64. Jennings, G.H.

65. Kemp,

~
i'll<

& Southwell-Sander, G. "Anemia and
aggranuloevtosis during sulf anilamide
therapy"
Lancet 2:898-901 '37

H.A·~~,l'Aotion of

··

Sulfan1lam1de"
Texas State J. Med. 34: 208-2II • 38

66. Klng, J.T.;Henschel, A.F.& Green, B.8. "Influence
of prontosil soluble on Beta Hem.
.
Jtreptococci growing 1n-t1ssue culture"
Proc. Soc. Exper.Biol. & Med. 38:812815 '38

BIBLIOGRAPHY
67. ______ ,&Leslie, A•. "Oxygen saturation ef
arterial blood in cyanosis from
sulfan11amide ..
A .M .•. IIo": 2069-71 I 38
68. Klein, J.R. & Harris, S.J. "Acet~lat1on of sulfan1lam1de 1n vitro
J.Biol. Chem. I24:6I3*626 '38
69. Kolmer,J.A.; Rule, A.M. •cWerner, M.L. "Sulfanilamide in treatment of exv.er1mental
streptococcal men1n.g~t1e'
Arch.Otolaryng. 27:.519-534 '38
70. Kreutmann, W.B. & Carr, J .L. "Effect of prontos.il
on Bl.oed cells"
Proc.Soc.Exper.Biol.&Med. 38:I9-2I
72.

& Mellon, R.R.
-Eitness, sulfanilamide and
pneumococcus infection inthe
rabbit"
Science 86:228-229 '37

Locke,A.;Locke,R.B.~ragdon,R,J,

71. Lloyd, V.E.;Ersk1ne,D.& Johnson, A.G. "Chemotherapy pf gonorrhea w1 th
Lancet 2:II60-II63 '38

aB 693"

72. Long, P.H. & Bliss, E.A. "The clinical use of sulfanilam1de and its derivatives in
the treatment of infectious disease"
Ann. Int.Med. II:575-592 '37
- - - - - ' - - - - ' "Sulfan1lamide and its derivatives"
.
Arch. Surg. 34:351-359 '37

74.

-----

, _ _ __....., "P-am1nobenzenesulphonam1de
and its der1vat1ves 11
A.I.A. I08: 11-17 '37

75. ----~'----.-........-_,Feinstone, W.H. "Mode ot
Action, clinical use & toxic
man1festat1ons 11 A.M.A. II2:II5-II9 1 39

....

;

~
~

.,.,,..

..

BIBLIOGRAPHY

76. ----~'-~~-=-~•-.,...,,_,_____ ,"The effects of
sulfapyridine, sulfan11amide and
realted compounds 1n baeterial In.f e ct ions " 11
Penn.M.J .42:483-491 '39 ·
77. _ _ _ _ _ , ______.,..,"use of sulfanilamide and
its derivatives in treatment of
infections due to streptococei"
South.M.J.30:479-487 '37
78. Mac Coll &: Durham, N.C. ~Clinical experiments with
sulfapyridine"
.
1
J.B ediat. 14:277-289 39
79. Jlainzer,

F.s.

"Sulfanilamide rash"
Penn.M .J. 4I: 386-387 '38

80. Marshall, E.X.Jr. "Determination of sulfanilamide
1n the blood and urine"
Proc.Soc.Exper.Biol.&Med. 36:422424 '37

SI.
82.

-----

----

, "certain phases of pharmacological
pr~erties of sul4in11amide"
Mj.Ann. District of Columbia 7:5-7 '38

, Cutt1ng,w.c. &: Emerson,K,Jr. "The toxicity
of sulfan1lam1de"
A.M.A.II0:252-257 '38

-----•---.--'
.. "Sulfanilamide,
absorption and excretion": method
for determination in blood and urine"
A.M.A.108:953-957
84.

------

, &: Walzl, E.M. "cyanosis from sulfan-

ilamide ..
Bull.Johns Hopkins Hosp. 6I:I4o-I44
'37

85. McGuire,P.R. &: J.P. "Aggranulocytosis following use
of sulfanilamide"
.
Illinois M.J. 73:425-426 '38 ·
86;. McXinley,E.B.; •rree,E.G. & Meck, J~S. ttsulfanil-

am 1de and virus di seaaes ", ·
~

~
.:'•

:

Science 87:43-44 '38

BIBLIOGRAPHY

87. McKinney,R •.A. &Mellon,R.R. "Sulf'anilamide-- and
the macrophage response to hemolytic

streptococcdc peritonitis in mice"
37:333-336 '37

Proc~Soc.Bxper.Biol.&Med.

88. Mellon, R.R. "A new approach to the therapete1s of
hemolytic streptococ_cal infections''
Proe.Soe.E.xper.Biol.&Med. 34:474-6 1 36
89.
90.

------~------

,& Bambas, L.L. "Bacteriostat1c effect
of sulfanilam1den
·
Proo ,Soc .Ex}>er .aiol .& Med. 36: 68 2- 3 ' 37
, "New obseJ'vat1ons on the
___m_e_c_han
......._ism of Aetien o~ sulfan1lamide"

.&

llihRec.,:<£46: 247;;.;248. '3'1:".

9I.

_ _ _ _ _ ,&_ __,____ , "Fibrinolytis

or

hemolytic

streptococci and their-variabll1~"
Proc.Soc.Exper.B1ol.&Med. 33:45I-J •35

92. Mellon, R.R.; Gross ,P. & EJooper ~ .F ,B. " Experimental

studies with sulfanilamide and with
prontos1l in hemolytic streptoooccic
infections"
·
A.M.A. !08: 1858-1865 I 37

, "Sulfanilam1de Therapy
Infections"
Published by c.C.Thomas, Baltimore,Kd.
1938.
94._M~_qv:ill,~-'~-~tG!_ .. ~-·~Q_hin&.rd.:.,..J .J. " Skin eruptions
(on Areas exposed to sunlight) 1n
-patients rece1 ving sulfan1lam1de"
A.M.A. 109:1008 '37

---

,

,

---o..,.f~Bacterial

95. Mull, J.W. & Smit~- J.T. "Effect of sulfanilam1de
on oxygen capacity of the blood"
A.M.~. 110:439-440 '38

"'

96. Myers, G.B.;Vonder-Heide E.c. & Balcersk1, M.•
"Exfo11at1ve dermatitis following
Silfanilamide"

A.M.A. 109: 1938 -1984 '37

97. Heal, J.B.

,,...
:·;~,

" '.h'eatment •& acute infections of the
Central Nervous System"
A.M.A. III:I353 -6 '38

BIBLIOGRAPHY .

98. Newman, B.A. & Sharlit, H. "Sulfan1lam1de; a

photosens1t1z1ng agent of the skin"
A.M.A. I09:I036-37 '37

99. OSSQod., E.E. "Culture

of human marrow; studies on
the mode of action of sultanilamide"

A.M.A.II0:349-356 '38

100.

"Culture of Humaa Marrow ..
Texas State J •.Med. 34:206-208 '38

IOI.

, "Culture of Human Marrow"; comparative
studies of the effects of sulfanilam1de"
Arch.Int.Med. 62: I8I-I98 *38

102. Ottenberg,R. & Fox, C,L, Jr. "Explanation for

c7anos.1s of sulfan11amide therap7tt

Proc.Soc,Exper.B1o~.&M:ed.

38:479-81 '38

I03. Paton, J.P.J. & Eaton, J.C. "Sulfhemoglobinemia
following the administration of
sulfanilamide"
Lancet l:II59-II62 '27

Io4. Parne,

s.

"Acetan1lide poisoning; a clin1ca1
experimental study" .
.
J .Pharmacol. & Exper. T herap,_53:4oI-

408

I

35

,..

105. Proom, H. "Metood of estimating sulfanilamide in
the blood, etc."

Lancet I: 260 ' 38

I06. Raiziss, G.W.; Severa:c, M. et al. "Chemotherap7 ·

of sulfan1lamide and prontosil soluble"
J.Chemotherap7 I4:9I-I05 '38

I07. Rosenblum, P. & A.H. "Severe hemolytic anemia d-ae
to sulfan1lam1de"
Arch. Pediat.

55:~1-512

1

38

I98. Rosenthal, S,M. "Studies in Chemotherap7tt
Pub.Health Rep. 52:I92-I96 •37
109.

~~~~-

, "Studies in Chemotherapy; effect of
sulfan1lam1de on pneumaaoce1 in ?itro"
Pub.Health Rep. 52:48-53 '37

BIBLIOGRAPHY
IIO. Roth, Lr.B. "Sulfan11amide therapy from the
pharmacologieal view point"
.M. Ann. District of Columbia 7:I7I-I80

1

38

III. Rous, P. "Nature and the Doctor"
· Diplomate II:39-47 • 39
II2. Schonberg, I.L. ".Purpuris and scarl1t1n1form
eruption following administration of
sulfanilamide"
A•.M.A. 109: 1035-37 ' 3$
II3. Schulte, T.L. "History of the developnent of
sulfan1lam1de"
Proc.Staff Meet • .Mayo Cl1n. 13:53-60 '38
II4. Schwartz, W.F.; Garr1n, C.F. & Koletsky, s.
•:ratal granulocytopenia from sulfanilam1de"
A•.M.A. 110:368-370 1 38

Il5j Schwentker, FF. & Gelman, s. "Sulfanilamide rashu
Bull. Johns Hopkins Hosp. 6I:I36I39 I 37
II6. Smith, A. "The chemotherapy of streptococcal
infections"
.
Lancet 2:1064-1070 1 37
II7. Southworth, H. "'Acidosis associated with administration of sulfanilamide"
P roc.Soc.Exper.Biol.&Ued.3658-61 '37
IIS. Stewart, J

.:o.;
9

Rourke, .M.; Allen, J .G.
Acetylation of sulfan1lam1de"
Surgery 5:232-236 '39

II9. Stoness, J.F. ''Kethemoglob1nem1a and prontylin"

New York State J. Med. 37:II39-4o •37

120. Swift, H.F. "The action of sulfanilamide in
Rheumatic fever"
A.M.A.110:426-428 ' 38
121. Tedder, ·H. "The skin after sulfan1lam1de 't#herapy"

Arch. Dermat. & Syph. 39:224-228 '39

BIBLIOGRAPHY
I22. Warren, J.iStreet, J.A. & Stokinger,H.E.
'Influence of sulfan11amide and related
compounds upon oxidation-reduction
potentials of hemolytic.streptococci"
Proo.Soc.Exper.Biol.& Med. 40: 208-212 1 39
123. Weinberg, M.H.; Mellon, R.R. & Shinn, L.
"Two oases of streptococcic menlngi tis

treated successfully with aulfanilamidett
A.M.A. 108:1948-52 '37

124. Welch, H.; Wentworth,J.A. & Bickle, F.L.

"The
use of sulfanilamide in the diagnosis
and treatment off'Brucella abortus"
A.M.A. III:226-228 '38

125. Whitby, L. "Chemotherapy of pneumococcal and other
infectionsn
Lancet l:I2IO-I2I2 '38
126.

, "Sulfapyridine--effective against
pneumococciu
Lancet 2: I095-I099 '38

127. Wood, H. "Fatality from a.cute hemolytic anemia.,
which developed from sulf anilamide
administration"
South. M.J. 31:646-648 '38
128. Young, C.J.

"Aggra.nuloc~tosis and p-aminobenzenesulphonamide'
Brit.M.J. 2:105- 106 1 37

